[
    {
        "parameters": {
            "embedding model": "BAAI/bge-small-en-v1.5",
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",
            "splitting method": "From scratch with Faiss vector store and SYNTACTIC splitter",
            "chunk size": 256,
            "overlap": 25,
            "top_k": 5,
            "max new tokens": 100,
            "re-ranking": 0,
            "top_n": 4
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What was the finding of the studies evaluating quinolones as a treatment option for 3GCephRE BSI?",
            "What was the finding of the studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE?",
            "What was the finding of the RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE?",
            "What is the level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible CRE?",
            "What is the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI?",
            "Is there sufficient evidence on plazomicin compared to colistin for the treatment of CRE infections?",
            "Is there a difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections?",
            "What is the evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections?",
            "What were the results of the retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections?",
            "What is the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin?",
            "What is the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP?",
            "What is the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections?",
            "What is the evidence from observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections?",
            "What are the general principles for antibiotic treatment in patients with CR-GNB infections?",
            "What is the suggested screening approach for patients undergoing colorectal and liver transplant surgery?",
            "What is the recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E undergoing colorectal surgery?",
            "What antibiotics should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers?",
            "What is recommended to be included in research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates?",
            "Can a recommendation be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery?",
            "What is a good practice for screening SOT recipients for CRAB before surgery?",
            "What type of clinical trials does the panel suggest designing to investigate CRAB colonization and targeted PAP?",
            "In transplant surgery other than renal transplant, what is the suggested duration of PAP?",
            "What is the risk of MDR-GNB infections in solid organ transplant (SOT) recipients, and what are the associated consequences?",
            "What is the suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB)?",
            "What is the outcome of a randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, particularly in fluoroquinolone-resistant (FQR) carriers?",
            "What is the association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery?",
            "What is the comprehensive approach required to reduce surgical site infections (SSIs)?",
            "What is recommended for standard operating procedures related to sampling site technique and microbiological methods?",
            "What should be considered when choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections?",
            "Why is it important to know the colonization status of a patient before solid organ transplantation (SOT)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "The studies found limited evidence on targeted quinolone therapy for 3GCephRE BSI, with one study reporting an association between quinolone treatment and lower mortality, but the analysis was limited by small sample sizes and potential biases, and therefore, there is no direct evidence to support the use of quinolones for targeted therapy.",
            "The studies, all of which were retrospective cohort studies with small sample sizes and high risk of bias, found no statistically significant differences between cephamycins and cefepime compared to carbapenems, providing low-certainty evidence for the use of cephamycins and cefepime in the treatment of pyelonephritis caused by 3GCephRE.",
            "The studies found that clinical or microbiological outcomes were similar between groups in all studies, with moderate certainty of evidence for ceftazidime-avibactam and very low certainty of evidence for eravacycline and ceftolozane-tazobactam in the treatment of IAI caused by 3GCephRE, although the trials were not powered to prove non-inferiority in these subgroups.",
            "There is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE, based on a small RCT (Tango-II) that showed significantly improved cure rates and non-significantly lower 28-day mortality.",
            "The level of evidence is moderate, based on several studies that showed better clinical outcomes, microbiological cure, and survival rates with aminoglycoside-containing regimens compared to tigecycline-containing regimens for cUTI.",
            "No, there is insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections, due to the suspension of the CARE-RCT study and limited available results.",
            "No, subgroup analysis of two RCTs (AIDA and OVERCOME) did not show statistically significant differences in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections.",
            "According to the CREDIBLE RCT, clinical and microbiological cure rates were similar between patients receiving cefiderocol monotherapy and combination therapy, but mortality data were not available and results were not presented separately for CRE.",
            "The study found that clinical cure was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam, but the study had a high risk of bias due to patient selection, baseline differences, and lack of data on carbapenem resistance.",
            "We suggest treatment with two in vitro active drugs (conditional recommendation for use, very low certainty of evidence), but no specific combination is recommended.",
            "We suggest ampicillin-sulbactam (conditional recommendation, low certainty of evidence).",
            "The available data suggest that cefiderocol does not have an advantage over other antibiotics, such as best available therapy (BAT) or high-dose extended-infusion meropenem, in terms of mortality, clinical, or microbiological outcomes in treating CRAB infections, and the evidence is of low certainty.",
            "Some observational studies suggest a significant association between polymyxin-carbapenem combination therapy and improved survival or clinical cure, while others do not; however, these studies are limited by their design and inability to assess the effects of specific combination regimens.",
            "The general principles include using optimal antibiotic dosing schemes, with attention to adverse effects, optimizing dosing and mode of administration by pathogen and indication, using therapeutic drug monitoring when available, prioritizing source control, and considering follow-up cultures in case of treatment failure to detect resistance development. Additionally, testing against new BLBLI and polymyxins is recommended for CR-GNB resistant to all blactams, and selecting antibiotic treatment with the least resistant antibiotic/s based on MICs relative to the breakpoints is recommended for pan-resistant CR-GNB.",
            "Rectal screening to identify ESCR-E carriers before surgery, taking into account local epidemiology.",
            "Targeted PAP is conditionally recommended in patients colonized with ESCR-E undergoing colorectal surgery, based on low certainty of evidence.",
            "Novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers.",
            "Research protocols should include postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used, and report antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.",
            "No, there is insufficient evidence for or against targeted PAP for patients colonized with CRE before surgery, and therefore no recommendation can be issued.",
            "It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRAB before surgery.",
            "The panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery, and investigating the efficacy of targeted versus routine PAP in CRAB carriers.",
            "The extension of PAP duration to 48-72 hours may be considered according to the type of transplant.",
            "SOT recipients are at high risk of MDR-GNB infections, with rates ranging from 3% to 53% depending on the type of transplant, and are associated with higher mortality compared to susceptible counterparts.",
            "Rectal screening is suggested to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
            "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate, with FQR carriers having a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers.",
            "Higher rates of postoperative infections, mainly surgical site infections (SSIs), were reported in patients with urinary colonization, particularly in ESCR-E carriers, with 31% developing postoperative infections, and 80% of these caused by the same colonizing strain.",
            "A comprehensive approach to reduce SSIs requires a combination of antibiotic-based interventions, such as targeted perioperative antibiotic prophylaxis (PAP), and best surgical practices, including minimization of surgical operative time, regulation of glucose and temperature, optimization of sterile techniques, and management of patient comorbidities, as well as heightening stewardship initiatives, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach.",
            "Standard operating procedures should be agreed upon according to national indications and evidence-based institutional protocols, including sampling site technique and microbiological methods.",
            "The choice of targeted PAP should take into consideration the limited number of options available for treating CRE infections, and avoid using novel compounds that may be needed for treating postsurgical infections.",
            "Knowing the colonization status before SOT is essential for the early implementation of infection control procedures, such as reducing the risk of intra-hospital and community spreading."
        ],
        "predicted answers": {
            "no additional prompt / no context": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-resistant Enterobacterales, or 3GCephrasporin-resistant K. pneumoniae, 3GCephraspor",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized",
                "Several studies have evaluated the use of quinolones as a treatment option for 3rd generation cephalosporin-resistant bloodstream infections (3GCephRE BSIs). Here are some key findings from these studies:\n\n1. Quinolones are effective against 3GCephRE BSIs caused by common pathogens such as Enterococcus faecium, Pseudomonas aeruginosa, and Klebsiella pneum",
                "Several studies have compared the effectiveness and safety of cephamycins (cefotetan and ceftriaxone), cefepime, and carbapenems (imipenem and meropenem) for the treatment of pyelonephritis caused by extended-spectrum \u03b2-lactamase producing Enterobacteriaceae (3GCephre).\n\nA systematic review and meta-analysis of 12 randomized controlled trials (",
                "Several randomized controlled trials (RCTs) have evaluated the effectiveness of various antibiotics for the treatment of intra-abdominal infections (IAIs) caused by third-generation cephalosporin-resistant Enterobacterales (3GCRE). Here are some key findings from these studies:\n\n1. Carbapenems: Carbapenems, such as imipenem, meropenem, and ertapen",
                "Meropenem-vaborbactam (MVB) is a carbapenem-beta-lactamase inhibitor combination antibiotic that has shown activity against certain carbapenem-resistant Enterobacterales (CRE), including those producing NDM-1 and OXA-48-type carbapenemases. The advantage of MVB over best available treatment for susceptible CRE is supported by several studies with varying levels of evidence",
                "The comparative effectiveness and safety of aminoglycosides versus tigecycline for the treatment of complicated urinary tract infections (cUTI), including uncomplicated cUTI, have been studied in several randomized controlled trials (RCTs) and meta-analyses.\n\nA systematic review and meta-analysis of 11 RCTs involving 3,512 patients published in the Cochrane Database of Systematic Reviews in",
                "Plazomicin and colistin are both antibiotics used in the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), but the evidence comparing the two drugs in terms of efficacy, safety, and optimal use is still evolving.\n\nPlazomicin is a new generation aminoglycoside with improved activity against CRE compared to older aminoglycosides. A phase 3 clinical trial,",
                "Several studies have investigated the difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with infections caused by Carbapenem-resistant Enterobacterales (CRE), including those caused by Klebsiella pneumoniae and other Enterobacterales. The results of these studies have been inconsistent.\n\nSome studies have reported no significant difference in 28-day mortality",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE), including Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa. The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is still emerging, and the optimal approach is not yet fully established.",
                "I apologize for any confusion, but I cannot provide you with the specific results of a retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections as there seems to be no published study with that exact title and inclusion criteria.\n\nHowever, there have been several studies investigating the effectiveness and safety of ceft",
                "CRPA (Carbapenem-resistant Pseudomonas aeruginosa) infections can be challenging to treat due to the resistance of the bacteria to many antibiotics. Polymyxins, aminoglycosides, and fosfomycin are commonly used antibiotics for the treatment of CRPA infections.\n\nPolymyxins, such as polymyxin B and E, are considered the first-line antibiot",
                "For patients with CRAB (Clostridioides difficile-related complications, including severe colitis, fulminant colitis, toxic megacolon, and sepsis) who are susceptible to sulbactam and have healthcare-associated pneumonia (HAP) or ventilator-associated pneumonia (VAP), the suggested treatment may depend on the severity of the infection and the patient's overall condition.\n\nFirst",
                "Cefiderocol is a siderophore cephalosporin antibiotic that is approved for the treatment of complicated intra-abdominal infections, including those caused by susceptible Gram-negative bacteria. CRAB (community-acquired or nosocomial acquisition, recurrent or persistent, intra-abdominal infections) is a specific type of intra-abdominal infection.\n\nSeveral studies have evaluated the effic",
                "Polymyxin-carbapenem combination therapy has been studied as a potential treatment option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections based on the synergistic effect of both antibiotics. However, the evidence from observational studies on the effectiveness of this combination therapy is limited and often inconsistent.\n\nOne study published in the Journal of Antimicrobial Chemotherapy in 201",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections are a significant challenge in clinical microbiology due to the increasing resistance of these bacteria to commonly used antibiotics. Here are some general principles for antibiotic treatment in patients with CR-GNB infections:\n\n1. Identify the specific CR-GNB causing the infection through microbiological culture and susceptibility testing. This information is crucial for selecting the most effective antibi",
                "Patients undergoing colorectal and liver transplant surgery require careful preoperative evaluation due to the complex nature of these procedures and the potential for complications. Here are some suggested screening approaches for these patients:\n\n1. Colorectal Transplant Surgery:\n- Preoperative assessment should include a thorough history and physical examination, with a focus on the gastrointestinal system.\n- Laboratory tests: Complete blood count, coagulation studies, electro",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Resistive-Escherichia coli (ESCR-E) undergoing colorectal surgery is not well-defined due to a lack of clear consensus in the literature. However, some guidelines suggest considering PAP based on the risk of surgical site infection (SSI) and the specific characteristics of the patient and the organ",
                "Extensively drug-resistant Enterococci (ESCR-E) and extensively drug-resistant Pseudomonas aeruginosa (ESCR-PA) are bacteria that have developed resistance to most or all available antibiotics. The treatment of infections caused by these bacteria is a challenge, and the use of last-resort antibiotics should be reserved for specific cases.\n\nThe European Society of Clinical Microbiology and Infectious Dise",
                "Research protocols investigating the impact of targeted PAP (pneumococcal and other encapsulated bacteria prevention using antibiotics) in reducing post-transplant infections among Extended-Spectrum Cephalosporin Resistant-Enterococcus (ESCR-E) colonized Solid Organ Transplant (SOT) candidates should include the following elements:\n\n1. Study Design: Clearly define the study design, including the type of study (",
                "Yes, a recommendation can be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery. The goal of PAP is to reduce the risk of surgical site infections (SSIs). In patients colonized with CRE, the risk of developing SSIs is increased due to the potential for carrying antibiotic-resistant bacteria. Therefore, targeted",
                "Screening SOT (solid organ transplant) recipients for CRAB (chronic rejection, acute rejection, banff lesions) before surgery involves a comprehensive evaluation to assess the current status of the transplanted organ and the overall health of the recipient. Here are some good practices for screening SOT recipients for CRAB before surgery:\n\n1. Review of medical history: A thorough review of the recipient's medical history, including details of the transplant procedure",
                "To investigate CRAB (Candida auris-related bloodstream infections) colonization and targeted PAP (positive blood culture identification and antimicrobial stewardship), the following types of clinical trials could be suggested:\n\n1. Prospective observational studies: These studies can be used to assess the prevalence and incidence of CRAB colonization in different patient populations and settings. They can also evaluate the effectiveness of targeted PAP in identifying CRAB in",
                "In transplant surgery other than renal transplants, the suggested duration of post-anesthesia care unit (PACU) or post-operative recovery varies depending on the specific type of transplant and the individual patient's condition. Here are some general guidelines for different types of transplants:\n\n1. Liver transplant: Patients typically stay in the PACU for 1-2 days after the surgery. However, some patients may require a longer",
                "MDR-GNB (Multidrug-resistant Gram-negative bacteria) infections are a significant concern in solid organ transplant (SOT) recipients due to their increased susceptibility to infections and the potential for antibiotic resistance. The risk of MDR-GNB infections in SOT recipients varies depending on several factors, including the type of transplant, the underlying condition of the patient, and the exposure to healthcare environments.\n\nAccording to a",
                "The identification of fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) is important to reduce the risk of post-biopsy infections and potential development of antibiotic-resistant bacteria. Here are some suggested approaches to identify FQR-E carriers:\n\n1. Pre-biopsy urine culture: Ob",
                "A randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP (Prostate Antigen Percentage using ciprofloxacin as a urinary selective inhibitor of bacterial growth) and culture-based PSA (Prostate Specific Antigen) in patients undergoing Transrectal Ultrasound-Guided Prostate Biopsy (TRUSPB) would provide data on the diagnostic accuracy and utility",
                "Urinary colonization with MDR-GNB has been identified as a risk factor for postoperative infections in patients undergoing urologic surgery. The presence of MDR-GNB in the urine before surgery increases the likelihood of developing postoperative infections, particularly urinary tract infections (UTIs).\n\nStudies have shown that the incidence of urinary colonization with MDR-GNB is higher in patients undergoing urologic surgery compared to",
                "Reducing surgical site infections (SSIs) requires a comprehensive approach that addresses various factors before, during, and after surgery. Here are some key elements of a comprehensive approach to reducing SSIs:\n\n1. Preoperative preparation:\n   a. Proper patient selection and optimization\n   b. Timely and appropriate antibiotic prophylaxis\n   c. Controlling risk factors such as diabetes, obesity, and malnutrition\n   d.",
                "Standard Operating Procedures (SOPs) for sampling site techniques and microbiological methods are essential to ensure consistency, accuracy, and reliability of data obtained from environmental or laboratory investigations. Here are some recommended practices for developing SOPs in these areas:\n\n1. Sampling Site Techniques:\n\na. Define the sampling objectives, location, and frequency.\nb. Establish a chain of custody for samples to maintain their integrity from the time of collection to",
                "When choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections, several factors should be considered to optimize the effectiveness of the antibiotic prophylaxis and minimize the risk of selecting for antibiotic resistance or causing adverse effects. Some of these factors include:\n\n1. Timing of administration: PAP should be administered within one hour before the surg",
                "Colonization status refers to the presence of potentially harmful bacteria in the body, particularly in the gastrointestinal tract, that do not cause infection in a healthy individual but can cause infections after a solid organ transplantation (SOT). These infections, known as translocation infections, can lead to significant morbidity and mortality in transplant recipients.\n\nThe importance of knowing the colonization status of a patient before SOT lies in the fact that certain"
            ],
            "additional prompt / no context": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum \u03b2-lactamase producing Klebsiella pneumoniae (3GCephrasporin-resistant, or 3GCephrE), the recommended targeted therapy is usually a carbapenem antibiotic, such as meropenem or imipenem. Other options may include polymyxins or aminocoumarins,",
                "The evidence on the treatment of infections caused by third-generation cephalosporin-resistant bacteria (3GCRE) is organized through numerous studies, meta-analyses, and guidelines. These sources provide evidence on the effectiveness and safety of various antibiotics, including carbapenems, aminoglycosides, and polymyxins, among others. The Infectious Diseases Society of America (IDSA) and European Society of Clin",
                "Quinolones have shown effectiveness in treating 3GCephalosporin-resistant bloodstream infections (BSIs). However, resistance to quinolones is increasing, so their use should be reserved for infections caused by susceptible bacteria. Adverse effects, including peripheral neuropathy and tendinitis, should be monitored closely.",
                "The studies suggest that cephamycins and cefepime are comparable to carbapenems in terms of clinical cure rates for pyelonephritis caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE). However, higher resistance rates to cephamycins and cefepime may require larger doses or alternative agents.",
                "The RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3rd-generation cephalosporin-resistant (3GCephR) bacteria have shown that:\n\n1. Carbapenems (imipenem, meropenem) are effective in treating 3GCephR-IAI.\n2. Aminoglycosides (gentamicin,",
                "The level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible Carbapenem-resistant Enterobacterales (CRE) is high, based on numerous randomized controlled trials and meta-analyses demonstrating superior clinical response and microbiological eradication rates.",
                "The evidence for the advantage of aminoglycosides over tigecycline for complicated urinary tract infections (cUTI) is inconclusive. Some studies suggest that aminoglycosides may have similar efficacy to tigecycline, while others suggest that tigecycline may have a slightly better safety profile. Ultimately, the choice between these antibiotics depends on individual patient factors and clinician preference.",
                "Plazomicin, a new antibiotic, has shown promise in clinical trials for the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), including those that are resistant to colistin. However, more data from larger, randomized controlled trials are needed to definitively establish the superiority of plazomicin over colistin in terms of clinical outcomes, safety, and resistance development. Therefore, the evidence is not yet sufficient",
                "Yes, there are studies suggesting that colistin-carbapenem combination therapy may have a lower 28-day mortality rate compared to colistin monotherapy in patients with Carbapenem-resistant Enterobacteriaceae (CRE) infections. However, the evidence is not definitive, and more research is needed to confirm these findings. It's important to note that individual patient outcomes can vary significantly based on factors such as underlying health conditions and",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE). The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections comes from several clinical studies.\n\nA randomized controlled trial (RCT) by Bekas et al. (2019) showed that monotherapy with cefiderocol led to similar",
                "The retrospective cohort study found that ceftolozane-tazobactam was associated with a higher clinical cure rate (83.3%) compared to polymyxins or aminoglycosides (63.6%) in patients with MDR/XDR P. aeruginosa mixed infections. However, it's important to note that retrospective studies have limitations, and more well-designed studies are needed to confirm these",
                "For severe infections caused by CRPA (Carbapenem-resistant Pseudomonas aeruginosa), the recommended antibiotic regimens include:\n\n1. Polymyxins (e.g., polymyxin B or E) in combination with an aminoglycoside (e.g., gentamicin or tobramycin).\n2. Monotherapy with a newer polymyxin (e.g",
                "For patients with CRAB (Carbapenem-resistant Acinetobacter baumannii) and susceptible to sulbactam but resistant to other antibiotics in the setting of HAP (Healthcare-associated pneumonia) or VAP (Ventilator-associated pneumonia), the suggested treatment options may include:\n\n1. Polymyxins (e.g., colistin or polymyxin",
                "Cefiderocol is an antibiotic with activity against gram-negative bacteria, including those commonly responsible for CRAB (community-acquired or healthcare-associated carbapenem-resistant acinetobacter baumannii) infections. Several studies have shown that cefiderocol is effective in treating CRAB infections, with success rates similar to or superior to other antibiotics such as colistin and tigecycline. However, it",
                "Observational studies suggest that polymyxin-carbapenem combination therapy may be effective in treating CRAB (Carbapenem-resistant Acinetobacter baumannii) infections. However, high-quality randomized controlled trials are needed to provide stronger evidence of its efficacy and safety. The combination therapy may improve outcomes by synergistic effects of both antibiotics against carbapenem-resistant A. baumannii.",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections require specific antibiotic treatment due to their resistance to commonly used antibiotics. Here are some general principles for antibiotic treatment:\n\n1. Identify the specific CR-GNB causing the infection through laboratory testing.\n2. Choose an antibiotic that is active against the identified CR-GNB.\n3. Consider the site of infection, severity, and patient",
                "For patients undergoing colorectal transplant surgery, preoperative screening typically includes colonoscopy to assess for colon cancer or precancerous lesions. For liver transplant patients, screening may include hepatitis serology, imaging studies like ultrasound or CT scan, and tumor markers like AFP. The specific screening approach may vary depending on individual patient risk factors and transplant type. Always consult with a healthcare professional for personalized medical advice.",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Cephalosporin-Resistant Enterococci (ESCR-E) undergoing colorectal surgery is controversial. Some guidelines suggest considering alternative antibiotics for PAP, while others recommend using a different class of antibiotics altogether, such as aminoglycosides or glycopeptides. Ultimately",
                "The antibiotics that should be reserved for the treatment of extensively resistant bacteria (such as extensively drug-resistant Mycobacterium tuberculosis or carbapenem-resistant Enterobacteriaceae) include:\n\n1. Polymyxins (e.g., colistin)\n2. Aminoglycosides (e.g., amikacin, gentamicin)\n3. Tigecycline",
                "Recommended components for research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates include:\n\n1. Study design: Randomized controlled trials (RCTs) or observational studies.\n2. Study population: ESCR-E colonized SOT candidates.\n3. Intervention: Targeted PAP (pre-transplant antimicrobial prophylaxis)",
                "Yes, a recommendation can be issued for targeted PAP for patients colonized with CRE before surgery to reduce the risk of surgical site infections caused by these bacteria. However, the specific antibiotic choice should be based on local resistance patterns and potential for cross-resistance. Consult local guidelines and infectious disease specialists for the most appropriate antibiotic selection.",
                "A good practice for screening Solid Organ Transplant (SOT) recipients for CRAB (Chronic Renal Allograft Abolition) before surgery is to assess their renal function with regular serum creatinine levels and estimated glomerular filtration rate (eGFR). Additionally, monitoring for proteinuria, hematuria, and signs of allograft dysfunction is essential. If there are concerns, a renal biopsy may be necessary",
                "To investigate CRAB (Clostridioides difficile-related antibiotic-associated bacterial) colonization and targeted PAP (phage-based antibiotic prophylaxis), the panel would suggest designing randomized controlled trials (RCTs) with a placebo or active comparator arm. These trials should include adequate sample size, proper power analysis, and appropriate endpoints to assess the efficacy and safety of targeted PAP in preventing CRAB colon",
                "In transplant surgery other than renal transplant, the suggested duration of post-operative positive airway pressure (PAP) varies depending on the specific type of transplant and individual patient's condition. Generally, it ranges from a few days to several weeks. For example, in liver transplant, PAP may be used for a few days to help prevent respiratory complications. In heart-lung transplant, PAP may be required for several weeks to help the",
                "The risk of Multidrug-resistant Gram-negative bacterial (MDR-GNB) infections in solid organ transplant (SOT) recipients is relatively high due to the use of immunosuppressive medications. These infections can lead to serious complications such as sepsis, organ failure, and increased mortality. Common MDR-GNB pathogens include P. aeruginosa, Acinetobacter baumannii, and Kle",
                "The suggested approach to identify FQR-E carriers before TRUSPB includes:\n\n1. Obtaining a urine culture before the procedure.\n2. Sensitivity testing for fluoroquinolones in the urine culture result.\n3. Considering alternative antibiotics for prophylaxis if FQR-E is identified.\n\nIt's important to note that the decision to test for FQR-E should be based on local",
                "The specific outcome of the trial you're referring to is not readily available in a clear and short answer format, as I would need to access the study's results to provide an accurate response. However, in general, non-blinded trials may be subject to bias, and comparing ciprofloxacin PAP (prostate antimicrobial prostatease) to culture-based PAP (transrectal ultrasound-guided prostate bi",
                "Urinary colonization with MDR-GNB is a significant risk factor for postoperative infections in patients undergoing urologic surgery. These bacteria can cause infections during or after the procedure, leading to increased morbidity and mortality. Preoperative urine screening and appropriate antibiotic prophylaxis can help reduce the risk of these infections.",
                "A comprehensive approach to reducing surgical site infections (SSIs) includes:\n\n1. Preoperative preparation: Optimizing the patient's health, proper wound preparation, and prophylactic antibiotics.\n2. Intraoperative measures: Sterile environment, proper surgical technique, and use of sterile instruments.\n3. Postoperative care: Wound care, early ambulation, and appropriate use of drains and dressings.\n4.",
                "For standard operating procedures (SOPs) related to sampling site technique, it's important to follow these steps:\n\n1. Properly clean and prepare the sampling site.\n2. Use sterile equipment for sampling.\n3. Collect sufficient sample size.\n4. Transport samples to the lab in appropriate containers and at proper temperature.\n\nFor microbiological methods, SOPs should include:\n\n1. Properly handling and transporting samples.",
                "When choosing targeted PAP for CRE infections, consider the following factors:\n\n1. Type and location of the surgery: The risk of surgical site infection (SSI) varies depending on the type and location of the surgery.\n2. Patient risk factors: Factors such as age, comorbidities, and underlying conditions increase the risk of SSIs.\n3. Type and susceptibility of the CRE isolate: The specific type and susceptibility of",
                "Colonization of a patient with bacteria or other pathogens that can cause infections is important to consider before solid organ transplantation (SOT) because these infections can lead to graft failure, increased morbidity, and mortality. Immunosuppressive drugs used after transplantation can weaken the patient's immune system, making them more susceptible to infections. Knowing the colonization status allows healthcare providers to take appropriate measures to prevent or treat"
            ],
            "no additional prompt / context": [
                "Based on the context provided, the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE is a carbapenem (imipenem or meropenem) (strong recommendation for use, moderate certainty of evidence).",
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including Bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infections (IAI). For BSI, the MERINO trial compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-res",
                "The studies evaluating quinolones as a treatment option for 3GCephRE BSI were observational in design and the quinolone group was very small in all studies. There is no direct evidence on targeted quinolone therapy for 3GcephRE BSI, but favorable effects were observed in studies assessing Gram-negative bacteriaemia in general. However, given the paucity of data and observational design, there is very-low-",
                "None of the retrospective cohort studies found statistically significant differences between cephamycins and cefepime, and carbapenems for the treatment of pyelonephritis caused by 3GCephRE. All studies were at high risk of bias, and the sample sizes were very small, providing low-certainty evidence for the use of cephamycins and cefepime in this context.",
                "The MERINO trial was a randomized controlled trial (RCT) that compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-resistant Escherichia coli and K. pneumoniae. The study found that meropenem was non-inferior to piperacillin-tazobactam in terms of clinical cure and micro",
                "Based on the small RCT (Tango-II) study mentioned in the context, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam for susceptible CRE compared with the old antibiotics. However, it is important to note that the sample size was small, and more research is needed to confirm these findings.",
                "The certainty of the evidence for an advantage of aminoglycosides over tigecycline for cUTI is moderate. The evidence includes studies that have shown higher survival rates with aminoglycosides compared with non-aminoglycoside regimens in patients with carbapenem and colistin-resistant K. pneumoniae with a prevalent respiratory source [127]. Another study observed better clinical cure with amin",
                "Based on the context provided, there is insufficient evidence on the comparative efficacy of plazomicin versus colistin for the treatment of CRE infections. The CRaCKle cohort study showed all-cause mortality at 28 days was lower with plazomicin combination therapy compared to colistin combination therapy, but the study was suspended after 2 years and there is currently not enough data to make a definitive conclusion.",
                "Based on the available evidence from the AIDA and OVERCOME trials, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections [160, 179]. However, it is important to note that these trials included mostly patients with CRAB infections, and the results may not be generalizable to all types of CRE",
                "Based on the available evidence, there is low-certainty evidence for the non-inferiority of cefercol monotherapy compared to other antibiotics for MBL-producing CRE infections. A subgroup analysis of patients with MBL-producing CR-GNB infections showed statistically non-significant higher cure and microbiological eradication rates for cefercol, but there was no significant difference in mortality. However, a post",
                "The retrospective cohort study compared the outcomes of 100 patients treated with ceftolozane-tazobactam and 100 patients treated with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections. The study found that clinical care was higher (adjusted OR 2.63, 95% CI 1.31-5.3",
                "Based on the available evidence, it is recommended to treat severe infections caused by CRPA with two in vitro active drugs when using polymyxins, aminoglycosides, or fosfomycin (conditional recommendation for use, very low certainty of evidence). No specific combination recommendations can be provided.",
                "Based on the context provided, for patients with CRAB susceptible to sublactam and HAP/VAP, we suggest ampicillin-sublactam as the antibiotic of choice (conditional recommendation, low certainty of evidence).",
                "Based on the available evidence, the clinical and microbiological efficacies of cefiderocol versus other antibiotics in treating CRAB infections are similar. However, a subgroup analysis of patients with MBL-producing CRE infections showed statistically non-significant higher cure and microbiological eradication rates for cefiderocol, but the difference in mortality was not significant. The analysis did not separate CRE from other CR-GNB.",
                "Several observational studies have assessed the combination of polymyxins and carbapenems for CRAB infections, but the results are inconsistent. Some studies showed a significant association between the use of the combination and survival or clinical cure [198, 235, 247], while others did not [199, 244]. However, many of these studies included patients treated with a polymyxin-carbapen",
                "1. Antibiotic stewardship considerations are important when choosing antibiotics for CR-GNB infections, especially for last-resort antibiotics like colistin and new BLBLI.\n2. The current guidelines recommend targeting specific pathogens with appropriate antibiotics, especially for patients considered at high risk for CR-GNB infections during the empirical treatment phase.\n3. For CR-GNB that are resistant to all b",
                "Based on the context provided, it is suggested to implement rectal screening to identify Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers before colorectal and liver transplant surgery, according to the local epidemiology. This is a conditional recommendation with low certainty of evidence. It might also be a good practice to screen all SOT recipients for ESCR-E before surgery, according to the",
                "Based on the evidence presented in the context, a conditional recommendation for use of targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery is made, with a low certainty of evidence. This recommendation is based on two studies, one of which was a multicenter, non-randomized, non-blinded interventional study that showed a potential benefit of etapenem use in reducing postoperative infections in ESCR",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers. The",
                "1. Postsurgical monitoring of antibiotic resistance: This includes conducting rectal cultures for CRE colonization, especially if carbapenem-based PAP is used.\n        2. Reporting antimicrobial susceptibility: Researchers should report antimicrobial susceptibility results according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines.\n        3. Trial design considerations: The trial design",
                "Based on the current evidence, no definitive recommendation can be issued for or against targeted PAP for patients who are colonized with CRE before surgery. The available evidence is limited, and there is a need for well-designed clinical trials to evaluate the effectiveness, applicability, and safety of targeted PAP in CRE carriers undergoing high-risk surgical procedures, such as transplant surgery. These trials should consider rectal culture results, the limited number of options for treating",
                "It might be a good practice to screen all SOT recipients for CRAB before surgery according to the local epidemiology (ungraded good practice statement). Any change in procedures should follow a careful assessment of local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards, considering a prevalence >=10% as a cut-off for implementation evaluation (based on previous recommendation). The choice of targeted versus universal screening should be based on the local work",
                "The panel suggests designing clinical trials to investigate the incidence risk of CRAB infections in carriers versus non-carriers, especially for patients undergoing high-risk surgery. Additionally, the efficacy of targeted versus routine PAP in CRAB carriers should be investigated in clinical trials. These trials should consider rectal culture results, the limited number of options for treating CRE infections, and resistance monitoring to detect emerging resistance to the regimens used for targeted PAP.",
                "Based on the context provided, the suggested duration of PAP in transplant surgery other than renal transplant is 48-72 hours, according to some expert recommendations. However, it is important to note that there is currently no formal consensus on PAP duration in transplant surgery beyond renal transplant, and further research is needed to investigate the clinical impact of shorter versus longer PAP durations. Additionally, the duration of targeted PAP should align with current recommendations by international societies",
                "The risk of MDR-GNB infections in solid organ transplant (SOT) recipients varies depending on the type of organ transplanted and the geographic area. According to available data, SSIs are a common issue in SOT recipients, with highest rates observed for intestinal, liver, and pancreas transplantation. Intra-abdominal infections, especially in the early post-transplant period, are a significant concern for liver trans",
                "Based on the context provided, it is recommended to perform rectal screening to identify FQR-E carriers before TRUSPB. This is a conditional recommendation with moderate certainty of evidence.",
                "The randomized, non-blinded, multicenter trial compared ciprofloxacin PAP versus culture-based PAP in 1288 patients undergoing TRUSPB, including 15.8% FQR carriers. The study showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB",
                "The evidence suggests that patients with urinary colonization with MDR-GNB have a higher risk of postoperative infections, particularly SSIs, compared to noncolonized patients undergoing urologic surgery. However, studies directly comparing postoperative infections in MDR-GNB urinary carriers versus noncarriers are lacking. A small, prospective single-centre study reported that 15% of postoperative infections in patients receiving targeted PAP based",
                "The comprehensive approach required to reduce surgical site infections (SSIs) involves a combination of antibiotic-based interventions and best surgical practices. Antibiotic-based interventions include targeted preoperative antibiotic prophylaxis (PAP) for MDR Gram-negative bacteria (MDR-GNB) carriers, especially in areas with high burden and for high-risk surgery. Additionally, optimizing antibiotic stewardship initiatives is essential",
                "Based on the context provided, there is a recommendation for implementing rectal screening to identify Carbapenem-resistant Acinetobacter baumannii (CRAB) carriers before liver transplant surgery according to local epidemiology (conditional recommendation, low certainty of evidence). The choice of targeted versus universal screening should be based on local work organization and integrated within antibiotic and diagnostic stewardship guidance. Irrespective of the PAP, the knowledge of the",
                "1. Consider the local epidemiology of CRE infections and the incidence of CRE SSIs in your institution.\n2. The choice of targeted PAP should take into consideration the limited number of options available for the treatment of CRE infections, avoiding novel compounds that may be required for the treatment of postsurgical infections.\n3. Resistance monitoring should be performed through detection of MDR-CRE carriage after surgery and to detect emerging resistance to the regim",
                "It is important to know the colonization status of a patient before solid organ transplantation (SOT) because MDR-GNB (multidrug-resistant gram-negative bacteria) colonization has been associated with increased rates of postoperative infections and SSIs (surgical site infections) in SOT patients. Early detection of MDR-GNB carriers can inform contact precautions in SOT candidates and may be useful in guiding the treatment of"
            ],
            "additional prompt / context": [
                "A carbapenem (imipenem or meropenem) is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE (strong recommendation for use, moderate certainty of evidence).",
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including Bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infections (IAI). For BSI, the MERINO trial compared piperacillin-tazobactam with meropenem, but most studies showed no significant difference between groups. Observational data shows no differences in mort",
                "The studies evaluating quinolones as a treatment option for 3GCephRE BSI were observational in design and the quinolone group was very small in all studies. There is no direct evidence on targeted quinolone therapy for 3GcephRE BSI, but favorable effects were observed in studies assessing Gram-negative bacteriaemia in general. However, given the paucity of data and observational design, there is very-low-",
                "None of the retrospective cohort studies found statistically significant differences between cephamycins and cefepime, and carbapenems for the treatment of pyelonephritis caused by 3GCephRE. All studies were at high risk of bias, and the evidence provided low-certainty for the use of cephamycins and cefepime for this indication.",
                "The MERINO trial was a randomized controlled trial (RCT) that compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-resistant E. coli and K. pneumoniae. The study found that meropenem was non-inferior to piperacillin-tazobactam in terms of clinical cure and microbiological er",
                "Based on the small RCT (Tango-II) study, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam for susceptible CRE compared with the old antibiotics.",
                "The certainty of the evidence for an advantage of aminoglycosides over tigecycline for cUTI is moderate.",
                "Based on the context provided, there is insufficient evidence on the comparative efficacy of plazomicin versus colistin for the treatment of CRE infections. The CRaCKle cohort study showed all-cause mortality at 28 days was lower with plazomicin combination therapy compared to colistin combination therapy, but the study was suspended after 2 years due to enrolment difficulties and there is currently insufficient evidence on plazomic",
                "Based on the available evidence from the AIDA and OVERCOME trials, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections. (Moderate-certainty evidence)",
                "Based on the available evidence, there is low-certainty evidence for the non-inferiority of cefiderocol compared to other antibiotics for MBL-producing CRE infections. However, there is no clear evidence to recommend for or against the use of combination therapy with cefiderocol for CRE infections. The evidence is conflicting regarding the use of combination therapy versus monotherapy for CRE infections overall, with some studies suggesting better clinical outcomes",
                "The retrospective cohort study reported higher clinical care (adjusted OR 2.63, 95% CI 1.31-5.30) and lower nephrotoxicity (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam compared with polymyxins or aminoglycosides",
                "We recommend treating severe infections caused by CRPA with two in vitro active drugs when using polymyxins, aminoglycosides, or fosfomycin (conditional recommendation, very low certainty of evidence). No specific combination recommendations can be provided.",
                "Based on the context provided, for patients with CRAB susceptible to sulbactam and HAP/VAP, we suggest ampicillin-sublactam as the antibiotic of choice (conditional recommendation, low certainty of evidence).",
                "Based on the available evidence, we conclude on low-certainty evidence for the non-inferiority of cefiderocol compared to other antibiotics for MBL-producing CRE infections. However, there is limited information available to date, and we cannot make a definitive recommendation for or against the use of cefiderocol for CRAB infections.",
                "Several observational studies have shown an association between the use of polymyxin-carbapenem combinations and improved survival or clinical cure in CRAB infections. However, not all studies have reported positive results, and it's important to note that many of these studies included patients treated with various combination therapies, making it difficult to assess the specific effects of a polymyxin-carbapenem combination. High-certainty evidence against the use of",
                "1. Antibiotic stewardship considerations are important in the treatment of CR-GNB infections.\n2. The current guidelines recommend targeting specific pathogens with appropriate antibiotics based on local epidemiology during the empirical treatment phase.\n3. For CR-GNB that are resistant to all b-lactams, testing against new BLBLI and polymyxins is recommended.\n4. Follow-up cultures are recommended in",
                "Based on the context provided, it is suggested to implement rectal screening to identify Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers before colorectal and liver transplant surgery according to the local epidemiology (conditional recommendation, low certainty of evidence). It might also be a good practice to screen all SOT recipients for ESCR-E before surgery according to the local epidemiology (",
                "We conditionally recommend targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery. This recommendation is based on low certainty of evidence from two studies, one of which was a multicenter study showing a potential benefit of etapenem use in reducing postoperative infections in ESCR-E carriers [41]. However, it is important to note that there is a need for well-designed RCTs to provide more",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers. Car",
                "1. Postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used.\n2. Reporting antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.\n3. Designing clinical trials in ESCR-E carriers undergoing high-risk surgical procedures, considering the local",
                "Based on the current evidence, no definitive recommendation can be issued for or against targeted PAP for patients who are colonized with CRE before surgery. However, it is recommended to design clinical trials to assess the impact of CRE rectal screening in high-risk surgeries, including the effectiveness, applicability, and safety of targeted PAP following antimicrobial stewardship principles. These trials should consider rectal culture results, the limited number of options for treating C",
                "It is a good practice to screen all SOT recipients for CRAB before surgery according to the local epidemiology (ungraded good practice statement). Any change in procedures should follow a careful assessment of local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards, considering a prevalence >=10% as a cut-off for implementation evaluation (previous recommendation). The choice of targeted versus universal screening should be based on the local work organization and integrated",
                "1. Clinical trials comparing the incidence risk of CRAB infections in carriers versus non-carriers, especially for patients undergoing high-risk surgery.\n        2. Clinical trials investigating the efficacy of targeted versus routine PAP in CRAB carriers.",
                "Based on current recommendations from IDSA/ASHP/SIS/SHEA and other international societies, PAP should be discontinued within 24 hours after surgery in patients colonized with MDR-GNB for transplant surgery other than renal transplant as well. However, in some cases, extending PAP duration to 48-72 hours may be considered according to the type of transplant. Further research is needed to investigate the clinical impact of shorter versus",
                "The risk of MDR-GNB infections in SOT recipients ranges from 3% to 53%, with the highest rates observed for intestinal, liver, and pancreas transplantation. Intra-abdominal infections, particularly in the early post-transplant period, are common in liver transplant recipients, with a risk of ESBL and CRKP infections ranging from 6% to 13% and 3%",
                "We suggest rectal screening to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
                "The trial reported a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate for patients receiving culture-based PAP compared to ciprofloxacin PAP. FQR carriers had a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers. However, the study was not",
                "There is evidence suggesting an association between urinary colonization with MDR-GNB and postoperative infections in patients undergoing urologic surgery. However, further research is needed to identify the impact of MDR-GNB colonization and targeted preoperative antibiotic prophylaxis (PAP) based on preoperative cultures on postoperative infections. The optimal targeted PAP for different MDR-GNB should also be investigated according to the type of",
                "A comprehensive approach to reduce SSIs requires a focus on both antibiotic-based interventions and best surgical practices. This includes minimizing surgical operative time, regulating glucose and temperature, optimizing sterile techniques, and managing patient comorbidities. Additionally, heightening stewardship initiatives to monitor and contain the consequences of new prescription patterns, enhance surveillance protocols, improve local adherence to guidelines, and promote a multidisciplinary approach are essential",
                "1. It is recommended to consider rectal culture results for clinical trials of targeted PAP for CRE carriers undergoing surgery.\n2. The choice of targeted PAP should take into consideration the limited number of options available for the treatment of CRE infections, avoiding novel compounds that may be required for the treatment of postsurgical infections.\n3. Resistance monitoring should be performed through detection of MDR-CNB carriage after surgery and to detect emerging resistance to the",
                "1. Limited options for treating CRE infections: The choice of targeted PAP should consider the limited number of available options for treating CRE infections.\n        2. Avoiding novel compounds: Novel compounds that may be required for the treatment of postsurgical inctions should be avoided in targeted PAP.\n        3. Rectal culture results: Clinical trials of targeted PAP should be designed considering rectal culture results.\n        4. Resistance monitoring:",
                "It is important to know the colonization status of a patient before solid organ transplantation (SOT) because this information can help in the early implementation of infection control procedures to reduce the risk of intrahospital and community spreading of multidrug-resistant germs (MDR-GNB). This knowledge can also inform contact precautions and may be taken into consideration when treating postoperative infections. The choice of targeted versus universal screening for MDR-GNB colonization"
            ]
        },
        "metrics": {
            "no additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.10426927455870987,
                    "2_gram": 0.17232945312043874,
                    "3_gram": 0.12203449066382968,
                    "4_gram": 0.08598788681468703
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.23668217296509428,
                        "recall": 0.4109030657231275,
                        "fmeasure": 0.285740394312968
                    },
                    "rouge_L": {
                        "precision": 0.15572278316466392,
                        "recall": 0.2809290035071148,
                        "fmeasure": 0.1908752053324701
                    }
                },
                "METEOR": 0.23717818182947348,
                "BERTScore": {
                    "Precision": -0.003,
                    "Recall": 0.171,
                    "F1_measure": 0.083
                }
            },
            "additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.11141463788088923,
                    "2_gram": 0.18204904662284616,
                    "3_gram": 0.13031715085607568,
                    "4_gram": 0.09079129596816363
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.24730519574032211,
                        "recall": 0.4196049847717524,
                        "fmeasure": 0.2914223958282858
                    },
                    "rouge_L": {
                        "precision": 0.17372168561673687,
                        "recall": 0.2921140135388925,
                        "fmeasure": 0.2044809352091253
                    }
                },
                "METEOR": 0.2426199338470025,
                "BERTScore": {
                    "Precision": 0.04,
                    "Recall": 0.216,
                    "F1_measure": 0.127
                }
            },
            "no additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.12081775551668017,
                    "2_gram": 0.2220390139895074,
                    "3_gram": 0.20867658109003567,
                    "4_gram": 0.1694809780627205
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.39262081360867734,
                        "recall": 0.6952359161259993,
                        "fmeasure": 0.47839959422303074
                    },
                    "rouge_L": {
                        "precision": 0.2960652520318727,
                        "recall": 0.5417497590261967,
                        "fmeasure": 0.3659057515504738
                    }
                },
                "METEOR": 0.4743170423581453,
                "BERTScore": {
                    "Precision": 0.27,
                    "Recall": 0.514,
                    "F1_measure": 0.388
                }
            },
            "additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.14450400290807006,
                    "2_gram": 0.25763571136004615,
                    "3_gram": 0.24888898472520826,
                    "4_gram": 0.20636067856850976
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.46793042650001326,
                        "recall": 0.7040450967815939,
                        "fmeasure": 0.5250444506548323
                    },
                    "rouge_L": {
                        "precision": 0.384473493932396,
                        "recall": 0.590361347722723,
                        "fmeasure": 0.43558435522879135
                    }
                },
                "METEOR": 0.5121445961781058,
                "BERTScore": {
                    "Precision": 0.358,
                    "Recall": 0.558,
                    "F1_measure": 0.454
                }
            }
        }
    },
    {
        "parameters": {
            "embedding model": "BAAI/bge-small-en-v1.5",
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",
            "splitting method": "From scratch with Faiss vector store and SYNTACTIC splitter",
            "chunk size": 256,
            "overlap": 25,
            "top_k": 5,
            "max new tokens": 100,
            "re-ranking": 1,
            "top_n": 4
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What was the finding of the studies evaluating quinolones as a treatment option for 3GCephRE BSI?",
            "What was the finding of the studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE?",
            "What was the finding of the RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE?",
            "What is the level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible CRE?",
            "What is the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI?",
            "Is there sufficient evidence on plazomicin compared to colistin for the treatment of CRE infections?",
            "Is there a difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections?",
            "What is the evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections?",
            "What were the results of the retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections?",
            "What is the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin?",
            "What is the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP?",
            "What is the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections?",
            "What is the evidence from observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections?",
            "What are the general principles for antibiotic treatment in patients with CR-GNB infections?",
            "What is the suggested screening approach for patients undergoing colorectal and liver transplant surgery?",
            "What is the recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E undergoing colorectal surgery?",
            "What antibiotics should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers?",
            "What is recommended to be included in research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates?",
            "Can a recommendation be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery?",
            "What is a good practice for screening SOT recipients for CRAB before surgery?",
            "What type of clinical trials does the panel suggest designing to investigate CRAB colonization and targeted PAP?",
            "In transplant surgery other than renal transplant, what is the suggested duration of PAP?",
            "What is the risk of MDR-GNB infections in solid organ transplant (SOT) recipients, and what are the associated consequences?",
            "What is the suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB)?",
            "What is the outcome of a randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, particularly in fluoroquinolone-resistant (FQR) carriers?",
            "What is the association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery?",
            "What is the comprehensive approach required to reduce surgical site infections (SSIs)?",
            "What is recommended for standard operating procedures related to sampling site technique and microbiological methods?",
            "What should be considered when choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections?",
            "Why is it important to know the colonization status of a patient before solid organ transplantation (SOT)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "The studies found limited evidence on targeted quinolone therapy for 3GCephRE BSI, with one study reporting an association between quinolone treatment and lower mortality, but the analysis was limited by small sample sizes and potential biases, and therefore, there is no direct evidence to support the use of quinolones for targeted therapy.",
            "The studies, all of which were retrospective cohort studies with small sample sizes and high risk of bias, found no statistically significant differences between cephamycins and cefepime compared to carbapenems, providing low-certainty evidence for the use of cephamycins and cefepime in the treatment of pyelonephritis caused by 3GCephRE.",
            "The studies found that clinical or microbiological outcomes were similar between groups in all studies, with moderate certainty of evidence for ceftazidime-avibactam and very low certainty of evidence for eravacycline and ceftolozane-tazobactam in the treatment of IAI caused by 3GCephRE, although the trials were not powered to prove non-inferiority in these subgroups.",
            "There is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE, based on a small RCT (Tango-II) that showed significantly improved cure rates and non-significantly lower 28-day mortality.",
            "The level of evidence is moderate, based on several studies that showed better clinical outcomes, microbiological cure, and survival rates with aminoglycoside-containing regimens compared to tigecycline-containing regimens for cUTI.",
            "No, there is insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections, due to the suspension of the CARE-RCT study and limited available results.",
            "No, subgroup analysis of two RCTs (AIDA and OVERCOME) did not show statistically significant differences in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections.",
            "According to the CREDIBLE RCT, clinical and microbiological cure rates were similar between patients receiving cefiderocol monotherapy and combination therapy, but mortality data were not available and results were not presented separately for CRE.",
            "The study found that clinical cure was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam, but the study had a high risk of bias due to patient selection, baseline differences, and lack of data on carbapenem resistance.",
            "We suggest treatment with two in vitro active drugs (conditional recommendation for use, very low certainty of evidence), but no specific combination is recommended.",
            "We suggest ampicillin-sulbactam (conditional recommendation, low certainty of evidence).",
            "The available data suggest that cefiderocol does not have an advantage over other antibiotics, such as best available therapy (BAT) or high-dose extended-infusion meropenem, in terms of mortality, clinical, or microbiological outcomes in treating CRAB infections, and the evidence is of low certainty.",
            "Some observational studies suggest a significant association between polymyxin-carbapenem combination therapy and improved survival or clinical cure, while others do not; however, these studies are limited by their design and inability to assess the effects of specific combination regimens.",
            "The general principles include using optimal antibiotic dosing schemes, with attention to adverse effects, optimizing dosing and mode of administration by pathogen and indication, using therapeutic drug monitoring when available, prioritizing source control, and considering follow-up cultures in case of treatment failure to detect resistance development. Additionally, testing against new BLBLI and polymyxins is recommended for CR-GNB resistant to all blactams, and selecting antibiotic treatment with the least resistant antibiotic/s based on MICs relative to the breakpoints is recommended for pan-resistant CR-GNB.",
            "Rectal screening to identify ESCR-E carriers before surgery, taking into account local epidemiology.",
            "Targeted PAP is conditionally recommended in patients colonized with ESCR-E undergoing colorectal surgery, based on low certainty of evidence.",
            "Novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers.",
            "Research protocols should include postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used, and report antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.",
            "No, there is insufficient evidence for or against targeted PAP for patients colonized with CRE before surgery, and therefore no recommendation can be issued.",
            "It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRAB before surgery.",
            "The panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery, and investigating the efficacy of targeted versus routine PAP in CRAB carriers.",
            "The extension of PAP duration to 48-72 hours may be considered according to the type of transplant.",
            "SOT recipients are at high risk of MDR-GNB infections, with rates ranging from 3% to 53% depending on the type of transplant, and are associated with higher mortality compared to susceptible counterparts.",
            "Rectal screening is suggested to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
            "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate, with FQR carriers having a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers.",
            "Higher rates of postoperative infections, mainly surgical site infections (SSIs), were reported in patients with urinary colonization, particularly in ESCR-E carriers, with 31% developing postoperative infections, and 80% of these caused by the same colonizing strain.",
            "A comprehensive approach to reduce SSIs requires a combination of antibiotic-based interventions, such as targeted perioperative antibiotic prophylaxis (PAP), and best surgical practices, including minimization of surgical operative time, regulation of glucose and temperature, optimization of sterile techniques, and management of patient comorbidities, as well as heightening stewardship initiatives, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach.",
            "Standard operating procedures should be agreed upon according to national indications and evidence-based institutional protocols, including sampling site technique and microbiological methods.",
            "The choice of targeted PAP should take into consideration the limited number of options available for treating CRE infections, and avoid using novel compounds that may be needed for treating postsurgical infections.",
            "Knowing the colonization status before SOT is essential for the early implementation of infection control procedures, such as reducing the risk of intra-hospital and community spreading."
        ],
        "predicted answers": {
            "no additional prompt / no context": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-resistant Enterobacterales, or 3GCephrasporin-resistant K. pneumoniae, 3GCephraspor",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized",
                "Several studies have evaluated the use of quinolones as a treatment option for 3rd generation cephalosporin-resistant bloodstream infections (3GCephRE BSIs). Here are some key findings from these studies:\n\n1. Quinolones are effective against 3GCephRE BSIs caused by common pathogens such as Enterococcus faecium, Pseudomonas aeruginosa, and Klebsiella pneum",
                "Several studies have compared the effectiveness and safety of cephamycins (cefotetan and ceftriaxone), cefepime, and carbapenems (imipenem and meropenem) for the treatment of pyelonephritis caused by extended-spectrum \u03b2-lactamase producing Enterobacteriaceae (3GCephre).\n\nA systematic review and meta-analysis of 12 randomized controlled trials (",
                "Several randomized controlled trials (RCTs) have evaluated the effectiveness of various antibiotics for the treatment of intra-abdominal infections (IAIs) caused by third-generation cephalosporin-resistant Enterobacterales (3GCRE). Here are some key findings from these studies:\n\n1. Carbapenems: Carbapenems, such as imipenem, meropenem, and ertapen",
                "Meropenem-vaborbactam (MVB) is a carbapenem-beta-lactamase inhibitor combination antibiotic that has shown activity against certain carbapenem-resistant Enterobacterales (CRE), including those producing NDM-1 and OXA-48-type carbapenemases. The advantage of MVB over best available treatment for susceptible CRE is supported by several studies with varying levels of evidence",
                "The comparative effectiveness and safety of aminoglycosides versus tigecycline for the treatment of complicated urinary tract infections (cUTI), including uncomplicated cUTI, have been studied in several randomized controlled trials (RCTs) and meta-analyses.\n\nA systematic review and meta-analysis of 11 RCTs involving 3,512 patients published in the Cochrane Database of Systematic Reviews in",
                "Plazomicin and colistin are both antibiotics used in the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), but the evidence comparing the two drugs in terms of efficacy, safety, and optimal use is still evolving.\n\nPlazomicin is a new generation aminoglycoside with improved activity against CRE compared to older aminoglycosides. A phase 3 clinical trial,",
                "Several studies have investigated the difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with infections caused by Carbapenem-resistant Enterobacterales (CRE), including those caused by Klebsiella pneumoniae and other Enterobacterales. The results of these studies have been inconsistent.\n\nSome studies have reported no significant difference in 28-day mortality",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE), including Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa. The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is still emerging, and the optimal approach is not yet fully established.",
                "I apologize for any confusion, but I cannot provide you with the specific results of a retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections as there seems to be no published study with that exact title and inclusion criteria.\n\nHowever, there have been several studies investigating the effectiveness and safety of ceft",
                "CRPA (Carbapenem-resistant Pseudomonas aeruginosa) infections can be challenging to treat due to the resistance of the bacteria to many antibiotics. Polymyxins, aminoglycosides, and fosfomycin are commonly used antibiotics for the treatment of CRPA infections.\n\nPolymyxins, such as polymyxin B and E, are considered the first-line antibiot",
                "For patients with CRAB (Clostridioides difficile-related complications, including severe colitis, fulminant colitis, toxic megacolon, and sepsis) who are susceptible to sulbactam and have healthcare-associated pneumonia (HAP) or ventilator-associated pneumonia (VAP), the suggested treatment may depend on the severity of the infection and the patient's overall condition.\n\nFirst",
                "Cefiderocol is a siderophore cephalosporin antibiotic that is approved for the treatment of complicated intra-abdominal infections, including those caused by susceptible Gram-negative bacteria. CRAB (community-acquired or nosocomial acquisition, recurrent or persistent, intra-abdominal infections) is a specific type of intra-abdominal infection.\n\nSeveral studies have evaluated the effic",
                "Polymyxin-carbapenem combination therapy has been studied as a potential treatment option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections based on the synergistic effect of both antibiotics. However, the evidence from observational studies on the effectiveness of this combination therapy is limited and often inconsistent.\n\nOne study published in the Journal of Antimicrobial Chemotherapy in 201",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections are a significant challenge in clinical microbiology due to the increasing resistance of these bacteria to commonly used antibiotics. Here are some general principles for antibiotic treatment in patients with CR-GNB infections:\n\n1. Identify the specific CR-GNB causing the infection through microbiological culture and susceptibility testing. This information is crucial for selecting the most effective antibi",
                "Patients undergoing colorectal and liver transplant surgery require careful preoperative evaluation due to the complex nature of these procedures and the potential for complications. Here are some suggested screening approaches for these patients:\n\n1. Colorectal Transplant Surgery:\n- Preoperative assessment should include a thorough history and physical examination, with a focus on the gastrointestinal system.\n- Laboratory tests: Complete blood count, coagulation studies, electro",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Resistive-Escherichia coli (ESCR-E) undergoing colorectal surgery is not well-defined due to a lack of clear consensus in the literature. However, some guidelines suggest considering PAP based on the risk of surgical site infection (SSI) and the specific characteristics of the patient and the organ",
                "Extensively drug-resistant Enterococci (ESCR-E) and extensively drug-resistant Pseudomonas aeruginosa (ESCR-PA) are bacteria that have developed resistance to most or all available antibiotics. The treatment of infections caused by these bacteria is a challenge, and the use of last-resort antibiotics should be reserved for specific cases.\n\nThe European Society of Clinical Microbiology and Infectious Dise",
                "Research protocols investigating the impact of targeted PAP (pneumococcal and other encapsulated bacteria prevention using antibiotics) in reducing post-transplant infections among Extended-Spectrum Cephalosporin Resistant-Enterococcus (ESCR-E) colonized Solid Organ Transplant (SOT) candidates should include the following elements:\n\n1. Study Design: Clearly define the study design, including the type of study (",
                "Yes, a recommendation can be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery. The goal of PAP is to reduce the risk of surgical site infections (SSIs). In patients colonized with CRE, the risk of developing SSIs is increased due to the potential for carrying antibiotic-resistant bacteria. Therefore, targeted",
                "Screening SOT (solid organ transplant) recipients for CRAB (chronic rejection, acute rejection, banff lesions) before surgery involves a comprehensive evaluation to assess the current status of the transplanted organ and the overall health of the recipient. Here are some good practices for screening SOT recipients for CRAB before surgery:\n\n1. Review of medical history: A thorough review of the recipient's medical history, including details of the transplant procedure",
                "To investigate CRAB (Candida auris-related bloodstream infections) colonization and targeted PAP (positive blood culture identification and antimicrobial stewardship), the following types of clinical trials could be suggested:\n\n1. Prospective observational studies: These studies can be used to assess the prevalence and incidence of CRAB colonization in different patient populations and settings. They can also evaluate the effectiveness of targeted PAP in identifying CRAB in",
                "In transplant surgery other than renal transplants, the suggested duration of post-anesthesia care unit (PACU) or post-operative recovery varies depending on the specific type of transplant and the individual patient's condition. Here are some general guidelines for different types of transplants:\n\n1. Liver transplant: Patients typically stay in the PACU for 1-2 days after the surgery. However, some patients may require a longer",
                "MDR-GNB (Multidrug-resistant Gram-negative bacteria) infections are a significant concern in solid organ transplant (SOT) recipients due to their increased susceptibility to infections and the potential for antibiotic resistance. The risk of MDR-GNB infections in SOT recipients varies depending on several factors, including the type of transplant, the underlying condition of the patient, and the exposure to healthcare environments.\n\nAccording to a",
                "The identification of fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) is important to reduce the risk of post-biopsy infections and potential development of antibiotic-resistant bacteria. Here are some suggested approaches to identify FQR-E carriers:\n\n1. Pre-biopsy urine culture: Ob",
                "A randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP (Prostate Antigen Percentage using ciprofloxacin as a urinary selective inhibitor of bacterial growth) and culture-based PSA (Prostate Specific Antigen) in patients undergoing Transrectal Ultrasound-Guided Prostate Biopsy (TRUSPB) would provide data on the diagnostic accuracy and utility",
                "Urinary colonization with MDR-GNB has been identified as a risk factor for postoperative infections in patients undergoing urologic surgery. The presence of MDR-GNB in the urine before surgery increases the likelihood of developing postoperative infections, particularly urinary tract infections (UTIs).\n\nStudies have shown that the incidence of urinary colonization with MDR-GNB is higher in patients undergoing urologic surgery compared to",
                "Reducing surgical site infections (SSIs) requires a comprehensive approach that addresses various factors before, during, and after surgery. Here are some key elements of a comprehensive approach to reducing SSIs:\n\n1. Preoperative preparation:\n   a. Proper patient selection and optimization\n   b. Timely and appropriate antibiotic prophylaxis\n   c. Controlling risk factors such as diabetes, obesity, and malnutrition\n   d.",
                "Standard Operating Procedures (SOPs) for sampling site techniques and microbiological methods are essential to ensure consistency, accuracy, and reliability of data obtained from environmental or laboratory investigations. Here are some recommended practices for developing SOPs in these areas:\n\n1. Sampling Site Techniques:\n\na. Define the sampling objectives, location, and frequency.\nb. Establish a chain of custody for samples to maintain their integrity from the time of collection to",
                "When choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections, several factors should be considered to optimize the effectiveness of the antibiotic prophylaxis and minimize the risk of selecting for antibiotic resistance or causing adverse effects. Some of these factors include:\n\n1. Timing of administration: PAP should be administered within one hour before the surg",
                "Colonization status refers to the presence of potentially harmful bacteria in the body, particularly in the gastrointestinal tract, that do not cause infection in a healthy individual but can cause infections after a solid organ transplantation (SOT). These infections, known as translocation infections, can lead to significant morbidity and mortality in transplant recipients.\n\nThe importance of knowing the colonization status of a patient before SOT lies in the fact that certain"
            ],
            "additional prompt / no context": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum \u03b2-lactamase producing Klebsiella pneumoniae (3GCephrasporin-resistant, or 3GCephrE), the recommended targeted therapy is usually a carbapenem antibiotic, such as meropenem or imipenem. Other options may include polymyxins or aminocoumarins,",
                "The evidence on the treatment of infections caused by third-generation cephalosporin-resistant bacteria (3GCRE) is organized through numerous studies, meta-analyses, and guidelines. These sources provide evidence on the effectiveness and safety of various antibiotics, including carbapenems, aminoglycosides, and polymyxins, among others. The Infectious Diseases Society of America (IDSA) and European Society of Clin",
                "Quinolones have shown effectiveness in treating 3GCephalosporin-resistant bloodstream infections (BSIs). However, resistance to quinolones is increasing, so their use should be reserved for infections caused by susceptible bacteria. Adverse effects, including peripheral neuropathy and tendinitis, should be monitored closely.",
                "The studies suggest that cephamycins and cefepime are comparable to carbapenems in terms of clinical cure rates for pyelonephritis caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE). However, higher resistance rates to cephamycins and cefepime may require larger doses or alternative agents.",
                "The RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3rd-generation cephalosporin-resistant (3GCephR) bacteria have shown that:\n\n1. Carbapenems (imipenem, meropenem) are effective in treating 3GCephR-IAI.\n2. Aminoglycosides (gentamicin,",
                "The level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible Carbapenem-resistant Enterobacterales (CRE) is high, based on numerous randomized controlled trials and meta-analyses demonstrating superior clinical response and microbiological eradication rates.",
                "The evidence for the advantage of aminoglycosides over tigecycline for complicated urinary tract infections (cUTI) is inconclusive. Some studies suggest that aminoglycosides may have similar efficacy to tigecycline, while others suggest that tigecycline may have a slightly better safety profile. Ultimately, the choice between these antibiotics depends on individual patient factors and clinician preference.",
                "Plazomicin, a new antibiotic, has shown promise in clinical trials for the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), including those that are resistant to colistin. However, more data from larger, randomized controlled trials are needed to definitively establish the superiority of plazomicin over colistin in terms of clinical outcomes, safety, and resistance development. Therefore, the evidence is not yet sufficient",
                "Yes, there are studies suggesting that colistin-carbapenem combination therapy may have a lower 28-day mortality rate compared to colistin monotherapy in patients with Carbapenem-resistant Enterobacteriaceae (CRE) infections. However, the evidence is not definitive, and more research is needed to confirm these findings. It's important to note that individual patient outcomes can vary significantly based on factors such as underlying health conditions and",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE). The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections comes from several clinical studies.\n\nA randomized controlled trial (RCT) by Bekas et al. (2019) showed that monotherapy with cefiderocol led to similar",
                "The retrospective cohort study found that ceftolozane-tazobactam was associated with a higher clinical cure rate (83.3%) compared to polymyxins or aminoglycosides (63.6%) in patients with MDR/XDR P. aeruginosa mixed infections. However, it's important to note that retrospective studies have limitations, and more well-designed studies are needed to confirm these",
                "For severe infections caused by CRPA (Carbapenem-resistant Pseudomonas aeruginosa), the recommended antibiotic regimens include:\n\n1. Polymyxins (e.g., polymyxin B or E) in combination with an aminoglycoside (e.g., gentamicin or tobramycin).\n2. Monotherapy with a newer polymyxin (e.g",
                "For patients with CRAB (Carbapenem-resistant Acinetobacter baumannii) and susceptible to sulbactam but resistant to other antibiotics in the setting of HAP (Healthcare-associated pneumonia) or VAP (Ventilator-associated pneumonia), the suggested treatment options may include:\n\n1. Polymyxins (e.g., colistin or polymyxin",
                "Cefiderocol is an antibiotic with activity against gram-negative bacteria, including those commonly responsible for CRAB (community-acquired or healthcare-associated carbapenem-resistant acinetobacter baumannii) infections. Several studies have shown that cefiderocol is effective in treating CRAB infections, with success rates similar to or superior to other antibiotics such as colistin and tigecycline. However, it",
                "Observational studies suggest that polymyxin-carbapenem combination therapy may be effective in treating CRAB (Carbapenem-resistant Acinetobacter baumannii) infections. However, high-quality randomized controlled trials are needed to provide stronger evidence of its efficacy and safety. The combination therapy may improve outcomes by synergistic effects of both antibiotics against carbapenem-resistant A. baumannii.",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections require specific antibiotic treatment due to their resistance to commonly used antibiotics. Here are some general principles for antibiotic treatment:\n\n1. Identify the specific CR-GNB causing the infection through laboratory testing.\n2. Choose an antibiotic that is active against the identified CR-GNB.\n3. Consider the site of infection, severity, and patient",
                "For patients undergoing colorectal transplant surgery, preoperative screening typically includes colonoscopy to assess for colon cancer or precancerous lesions. For liver transplant patients, screening may include hepatitis serology, imaging studies like ultrasound or CT scan, and tumor markers like AFP. The specific screening approach may vary depending on individual patient risk factors and transplant type. Always consult with a healthcare professional for personalized medical advice.",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Cephalosporin-Resistant Enterococci (ESCR-E) undergoing colorectal surgery is controversial. Some guidelines suggest considering alternative antibiotics for PAP, while others recommend using a different class of antibiotics altogether, such as aminoglycosides or glycopeptides. Ultimately",
                "The antibiotics that should be reserved for the treatment of extensively resistant bacteria (such as extensively drug-resistant Mycobacterium tuberculosis or carbapenem-resistant Enterobacteriaceae) include:\n\n1. Polymyxins (e.g., colistin)\n2. Aminoglycosides (e.g., amikacin, gentamicin)\n3. Tigecycline",
                "Recommended components for research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates include:\n\n1. Study design: Randomized controlled trials (RCTs) or observational studies.\n2. Study population: ESCR-E colonized SOT candidates.\n3. Intervention: Targeted PAP (pre-transplant antimicrobial prophylaxis)",
                "Yes, a recommendation can be issued for targeted PAP for patients colonized with CRE before surgery to reduce the risk of surgical site infections caused by these bacteria. However, the specific antibiotic choice should be based on local resistance patterns and potential for cross-resistance. Consult local guidelines and infectious disease specialists for the most appropriate antibiotic selection.",
                "A good practice for screening Solid Organ Transplant (SOT) recipients for CRAB (Chronic Renal Allograft Abolition) before surgery is to assess their renal function with regular serum creatinine levels and estimated glomerular filtration rate (eGFR). Additionally, monitoring for proteinuria, hematuria, and signs of allograft dysfunction is essential. If there are concerns, a renal biopsy may be necessary",
                "To investigate CRAB (Clostridioides difficile-related antibiotic-associated bacterial) colonization and targeted PAP (phage-based antibiotic prophylaxis), the panel would suggest designing randomized controlled trials (RCTs) with a placebo or active comparator arm. These trials should include adequate sample size, proper power analysis, and appropriate endpoints to assess the efficacy and safety of targeted PAP in preventing CRAB colon",
                "In transplant surgery other than renal transplant, the suggested duration of post-operative positive airway pressure (PAP) varies depending on the specific type of transplant and individual patient's condition. Generally, it ranges from a few days to several weeks. For example, in liver transplant, PAP may be used for a few days to help prevent respiratory complications. In heart-lung transplant, PAP may be required for several weeks to help the",
                "The risk of Multidrug-resistant Gram-negative bacterial (MDR-GNB) infections in solid organ transplant (SOT) recipients is relatively high due to the use of immunosuppressive medications. These infections can lead to serious complications such as sepsis, organ failure, and increased mortality. Common MDR-GNB pathogens include P. aeruginosa, Acinetobacter baumannii, and Kle",
                "The suggested approach to identify FQR-E carriers before TRUSPB includes:\n\n1. Obtaining a urine culture before the procedure.\n2. Sensitivity testing for fluoroquinolones in the urine culture result.\n3. Considering alternative antibiotics for prophylaxis if FQR-E is identified.\n\nIt's important to note that the decision to test for FQR-E should be based on local",
                "The specific outcome of the trial you're referring to is not readily available in a clear and short answer format, as I would need to access the study's results to provide an accurate response. However, in general, non-blinded trials may be subject to bias, and comparing ciprofloxacin PAP (prostate antimicrobial prostatease) to culture-based PAP (transrectal ultrasound-guided prostate bi",
                "Urinary colonization with MDR-GNB is a significant risk factor for postoperative infections in patients undergoing urologic surgery. These bacteria can cause infections during or after the procedure, leading to increased morbidity and mortality. Preoperative urine screening and appropriate antibiotic prophylaxis can help reduce the risk of these infections.",
                "A comprehensive approach to reducing surgical site infections (SSIs) includes:\n\n1. Preoperative preparation: Optimizing the patient's health, proper wound preparation, and prophylactic antibiotics.\n2. Intraoperative measures: Sterile environment, proper surgical technique, and use of sterile instruments.\n3. Postoperative care: Wound care, early ambulation, and appropriate use of drains and dressings.\n4.",
                "For standard operating procedures (SOPs) related to sampling site technique, it's important to follow these steps:\n\n1. Properly clean and prepare the sampling site.\n2. Use sterile equipment for sampling.\n3. Collect sufficient sample size.\n4. Transport samples to the lab in appropriate containers and at proper temperature.\n\nFor microbiological methods, SOPs should include:\n\n1. Properly handling and transporting samples.",
                "When choosing targeted PAP for CRE infections, consider the following factors:\n\n1. Type and location of the surgery: The risk of surgical site infection (SSI) varies depending on the type and location of the surgery.\n2. Patient risk factors: Factors such as age, comorbidities, and underlying conditions increase the risk of SSIs.\n3. Type and susceptibility of the CRE isolate: The specific type and susceptibility of",
                "Colonization of a patient with bacteria or other pathogens that can cause infections is important to consider before solid organ transplantation (SOT) because these infections can lead to graft failure, increased morbidity, and mortality. Immunosuppressive drugs used after transplantation can weaken the patient's immune system, making them more susceptible to infections. Knowing the colonization status allows healthcare providers to take appropriate measures to prevent or treat"
            ],
            "no additional prompt / context": [
                "Based on the context provided, the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE is a carbapenem (imipenem or meropenem) (strong recommendation for use, moderate certainty of evidence).",
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including Bloodstream infections (BSI), Urinary Tract Infections (UTI), pneumonia, and intra-abdominal infections (IAI). For each syndrome, the text discusses specific recommendations and good practice statements based on the available evidence.\n\n        For BSI, the main comparison is between BLBLI (amoxicillin-clav",
                "The studies evaluating quinolones as a treatment option for 3GCephRE BSI were very small and most of them reported quinolones as stepdown therapy for stable patients. There is no direct evidence on targeted quinolone therapy for 3GcephRE BSI, but favorable effects were observed in studies assessing Gram-negative bacteriaemia in general. However, given the paucity of data and observational design, there is very-low",
                "The studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE did not find statistically significant differences between groups in very small sample sizes. All studies were at high risk of bias, providing low-certainty evidence for cepamymcins and cefepime for the treatment of pyelonephritis caused by 3GCephRE.",
                "The MERINO trial was a randomized controlled trial (RCT) that compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-resistant Escherichia coli and K. pneumoniae. The study found that meropenem was non-inferior to piperacillin-tazobactam in terms of clinical cure and micro",
                "Based on the context provided, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam for susceptible CRE compared with the old antibiotics. However, it is important to note that the evidence comes from a small study with a non-significant difference in 28-day mortality and lower rates of renal-related adverse events in the meropenem-vaborbactam group. The certainty of the",
                "The level of evidence for the advantage of aminoglycosides over tigecycline for cUTI is moderate, based on studies that have shown better clinical cure and microbiological cure with aminoglycosides compared with tigecycline-based regimens [125, 126]. However, there is insufficient evidence for other comparisons and sources of infection.\n\n        It is important to note that the evidence is moderate due",
                "Based on the context provided, there is insufficient evidence on the comparative efficacy of plazomicin versus colistin for the treatment of CRE infections. The study that compared the two was suspended after 2 years due to enrolment difficulties, and the available results did not show statistically significant differences in all-cause mortality at 28 days between colistin combination therapy and plazomicin combination therapy in patients with CRE infections. Therefore",
                "Based on the available evidence from the AIDA and OVERCOME trials, there were no statistically significant differences in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy in patients with CRE infections (p 0.24 in AIDA and p 0.25 in OVERCOME). However, it is important to note that both studies were suspended prematurely and the results should",
                "Based on the available evidence, the use of cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is not clear-cut. The evidence for using cefiderocol monotherapy includes a study that showed similar clinical and microbiological efficacies compared to BAT, but with a higher mortality rate in the cefiderocol arm [121]. However, a subgroup analysis of patients with MBL-producing CR-GNB infections",
                "The retrospective cohort study included 100 patients each with MDR/XDR P. aeruginosa mixed infections, mostly pneumonia. The study found that clinical care was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03",
                "When treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin, it is suggested to use two in vitro active drugs (conditional recommendation for use, very low certainty of evidence). No specific combination recommendations can be provided.",
                "Based on the available evidence, the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP is sulbactam-based combination therapy. This is supported by observational studies demonstrating significantly lower 28-day mortality and unadjusted lower mortality with sulbactam-containing regimens compared with tigecycline-based therapy, despite high non-susceptibility rates to sublactam. However",
                "Based on the available evidence, the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections is not clear. The CREDIBLE RCT and APEKS-NP RCT did not show any advantage to cefiderocol over other antibiotics such as BAT, meropenem, or colistin-arbapamen in terms of clinical or microbiological eradication. There is also limited information on the clinical eff",
                "Several observational studies have assessed the use of polymyxin-carbapenem combination therapy for CRAB infections and have reported conflicting results. Some studies have shown a significant association between the use of the combination therapy and improved survival or clinical cure [198, 235, 247]. However, other studies did not show such an association [199, 244]. It is important to note that many of these studies",
                "1. Antibiotic stewardship considerations are important in the treatment of CR-GNB infections.\n2. The choice of antibiotics for CR-GNB infections is based on in vitro activity and the source of infection.\n3. For non-severe or low-risk CRPA infections, it is good clinical practice to consider using older antibiotics that are active against CR-GNB.\n4. For CR-GNB",
                "Based on the context provided, it is suggested to screen patients for Extended-Spectrum Cephalosporin-Resistant Enterobacterales (ESCR-E) before colorectal and liver transplant surgery according to the local epidemiology (conditional recommendation, low certainty of evidence). This recommendation might also apply to all SOT recipients as a good practice (ungraded good practice statement). The implementation of screening procedures should consider local prevalence, work",
                "Based on the available evidence, it may be a good practice to consider targeted PAP for patients colonized with ESCR-E undergoing colorectal surgery. This recommendation is supported by observational studies suggesting that targeted PAP may be effective in reducing SSIs in MDR-GNB carriers, although well-designed RCTs are needed to provide more robust evidence. The use of etapenem, a carbapenem antibiotic, has shown potential",
                "Based on the context provided, it appears that carbapenems are recommended to be used with caution in ESCR-E carriers for targeted PAP due to the risk of carbapenemases production. Therefore, carbapenems should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers. Instead, other antibiotics such as beta-lactamase inhibitors, quinol",
                "1. Postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used.\n2. Reporting antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.\n3. Designing clinical trials in ESCR-E carriers undergoing high-risk surgical procedures, considering the local",
                "Based on the current evidence, it is recommended that there is insufficient evidence for or against targeted PAP for patients who are colonized with CRE before surgery. Therefore, no definitive recommendation can be issued at this time. Future clinical trials should be designed to assess the impact of CRE rectal screening in high-risk surgeries, including adequate monitoring of infectious complications and development of antibiotic resistance following surgery.",
                "According to the context provided, a good practice for screening SOT recipients for CRAB before surgery involves assessing the local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards. If the prevalence is greater than or equal to 10%, it is recommended to consider implementing rectal screening to identify CRAB carriers before surgery. This recommendation is based on a conditional recommendation with low certainty of evidence. The choice of targeted versus universal",
                "The panel suggests designing clinical trials to investigate CRAB colonization and targeted PAP in high-risk patients, such as those undergoing transplant surgery. These trials should evaluate the effectiveness, applicability, and safety of targeted PAP in CRAB carriers. Specifically, they should consider rectal culture results for MDR-GNB screening, take into account the limited number of options for treating CRE infections, and perform resistance monitoring to detect emerging resistance to the regimens",
                "Based on current recommendations and expert opinion, the suggested duration of PAP in transplant surgery other than renal transplant varies. Some sources suggest administering PAP for less than 24 hours in kidney transplant, 24-48 hours in liver, heart, pancreas transplant, and 48-72 hours in intestinal/multivisceral and lung transplantation [5,18,62]. However, exceptions",
                "The risk of MDR-GNB infections in solid organ transplant (SOT) recipients varies widely, with estimates ranging from 3% to 53%, depending on the type of transplant and geographic location. The highest rates are observed for intestinal, liver, and pancreas transplantation. MDR-GNB infections are associated with higher mortality compared with their susceptible counterparts. Among nonfermenters, rates of CRAB",
                "Based on the context provided, it is suggested that local resistance patterns to fluoroquinolones, particularly with E. coli, should be evaluated to help guide PAP selection for FQR-E carriers undergoing TRUSPB. The use of entrapment, cefoxitin, and fosfomycin in PAP has been associated with reduced incidence of BSIs in FQR-E carriers. However, the optimal targeted PAP for carriers",
                "The randomized, non-blinded, multicenter trial compared ciprofloxacin PAP versus culture-based PAP in 1288 patients undergoing TRUSPB, including 15.8% FQR carriers. The study showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB",
                "Based on the available evidence, there is a relationship between urinary colonization with MDR-GNB and an increased risk of postoperative infections, particularly SSIs, in patients undergoing urologic surgery. However, the literature is limited, and there is insufficient evidence to recommend for or against screening and targeted preoperative antibiotic prophylaxis (PAP) based on MDR-GNB colonization status before urologic surgery. Further research is needed",
                "The comprehensive approach required to reduce SSIs involves a combination of antibiotic-based interventions and best surgical practices. Antibiotic-based interventions should focus not only on targeted preoperative antibiotic prophylaxis (PAP) but also on heightening stewardship initiatives to monitor and contain the consequences of new prescription patterns, enhance surveillance protocols, improve local adherence to guidelines, and promote a multidisciplinary approach.\n\n        Best",
                "Based on the context provided, it is recommended that any change in sampling site technique or microbiological methods for Carbapenem-resistant Acinetobacter baumannii (CRAB) screening should follow a careful assessment of local epidemiology and prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards. The implementation of screening procedures is suggested when the prevalence is >=10%. Evidence-based screening protocols, including",
                "1. Current guidelines recommend different PAP based on the type of solid organ transplant (SOT) and adjusting PAP in case of ongoing infections, but targeted PAP for CRE carriers is undefined [18, 45].\n        2. Recipient screening is recommended for lung transplant, and targeted PAP may be considered in high-risk patients for infection control purposes and adapting postsurgical empirical treatment [45].",
                "It is essential to know the colonization status of a patient before solid organ transplantation (SOT) because early identification of multidrug-resistant gram-negative bacteria (MDR-GNB) carriers can inform contact precautions in SOT candidates and may help in the management of postoperative infections. This knowledge can contribute to the implementation of infection control procedures to reduce the risk of intrahospital and community spreading. Limited data suggest that ESCR-E"
            ],
            "additional prompt / context": [
                "The recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE is a carbapenem (imipenem or meropenem) (strong recommendation for use, moderate certainty of evidence).",
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including Bloodstream infections (BSI), Urinary Tract Infections (UTI), pneumonia, and intra-abdominal infections (IAI). For BSI, the main comparison is between BLBLI (amoxicillin-clavulanate and piperacillin-tazobactam) and carbapenems, with",
                "The studies evaluating quinolones as a treatment option for 3GCephRE BSI were small and most of them reported quinolones as stepdown therapy for stable patients. There is no direct evidence on targeted quinolone therapy for 3GcephRE BSI, but favorable effects were observed in studies assessing Gram-negative bacteriaemia in general. However, there is very-low-certainty evidence for quinolone treatment for bacteria",
                "The studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE provided low-certainty evidence due to high risk of bias and inconsistent results. None of the studies found statistically significant differences between groups, but some studies suggested higher mortality with cephamycins or cefepime, particularly when MICs were elevated within the susceptible range.",
                "The MERINO trial compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-resistant E. coli and K. pneumoniae, but no specific RCTs were mentioned for IAI caused by 3GCephRE. The evidence base for the treatment of IAI caused by 3GCephRE is limited, and more well-designed studies are",
                "Based on the small study with moderate-certainty evidence, there is an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE. However, it is important to note that the evidence is not high due to the small sample size and the exclusion of non-susceptible strains in a subanalysis which decreased the difference between groups and made it non-significant.",
                "The certainty of the evidence for an advantage of aminoglycosides over tigecycline for cUTI is moderate. There is evidence from studies showing better clinical outcomes with aminoglycosides, but the evidence is not strong and there is insufficient evidence for other comparisons and sources of infection.",
                "Based on the context provided, there is insufficient evidence on the comparative efficacy of plazomicin versus colistin for the treatment of CRE infections. The study that compared the two was suspended after 2 years due to enrolment difficulties, and the available results did not show statistically significant differences in all-cause mortality at 28 days between the two regimens. Therefore, more research is needed to establish the superiority or equivalence of",
                "Based on the available evidence from the AIDA and OVERCOME trials, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections (moderate certainty of evidence). However, the results from a retrospective study suggest that colistin given alone or with a non-active antibiotic may be associated with higher mortality than",
                "Based on the available evidence, it is unclear whether cefiderocol monotherapy or combination therapy is superior for the treatment of CRE infections. The evidence for cefiderocol monotherapy versus combination therapy is conflicting, and the certainty of the evidence is low due to the observational nature and high risk of bias in most studies. In the few studies with adequate sample size and adjustment for confounders, the evidence seems to favor combination therapy for better clinical outcomes, particularly",
                "The retrospective cohort study reported higher clinical care (adjusted OR 2.63, 95% CI 1.31-5.30) and lower nephrotoxicity (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam compared to polymyxins or aminoglycosides",
                "When treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin, it is suggested to use two in vitro active drugs (conditional recommendation for use, very low certainty of evidence). No specific combination recommendations can be provided.",
                "Based on the context provided, the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP is sulbactam-based combination therapy. The evidence includes a retrospective study demonstrating significantly lower 28-day mortality with sulbactam-based treatment, despite high resistance rates to sublactam [215], and another retrospective study showing unadjusted lower mortality with cefoperazone-s",
                "Based on the available evidence, the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections is unclear. The CREDIBLE and APEKS-NP trials did not show any advantage to cefiderocol over other antibiotics in terms of clinical or microbiological outcomes. There is also limited evidence against the use of cefiderocol for CRAB infections. Other antibiotics, such as eravacycline",
                "Several observational studies have shown an association between the use of polymyxin-carbapenem combination therapy and improved survival or clinical cure in CRAB infections. However, the evidence is of low certainty due to the lack of specific data on the effects of a particular combination regimen, and some studies did not show a benefit. The largest and most well-designed study, a randomized controlled trial (RCT), did not find a significant difference in mortality",
                "1. Use in vitro active antibiotics on an individual basis, considering the source of infection.\n2. Consider antibiotic stewardship principles, including carbapenem use and stepdown therapy.\n3. For CR-GNB resistant to all b-lactams, test against new BLBLI and polymyxins, and consider the least resistant antibiotic based on MICs and optimal source control.\n4. Support antibi",
                "Based on the context provided, the suggested screening approach for patients undergoing colorectal and liver transplant surgery is rectal screening to identify Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers according to the local epidemiology (conditional recommendation, low certainty of evidence). It might also be a good practice to screen all SOT recipients for ESCR-E before surgery according to the local epid",
                "Based on the available evidence, it may be a good practice to consider targeted PAP for patients colonized with ESCR-E undergoing colorectal surgery. However, the certainty of evidence is low due to the observational study design and the lack of well-designed randomized controlled trials. Etapenem is one antibiotic that has shown potential benefits in reducing SSIs in ESCR-E carriers. However, more high-quality studies are needed",
                "Based on the available evidence, carbapenems should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers due to the risk of carbapenemases production.",
                "1. Postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used.\n2. Reporting antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.\n3. Designing clinical trials in ESCR-E carriers undergoing high-risk surgical procedures, considering the local",
                "Based on the current evidence, no definitive recommendation can be issued for or against targeted PAP for patients who are colonized with CRE before surgery. The local burden of CRE and patient-related risk factors for carrier status should be considered when designing clinical trials to assess the impact of CRE rectal screening and targeted PAP in high-risk surgeries. Postsurgical monitoring of resistance development to the antibiotics used for targeted regimens is also recommended.",
                "Based on the context provided, a good practice for screening SOT recipients for CRAB before surgery is to assess the local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards. If the prevalence is greater than or equal to 10%, it is recommended to consider implementing rectal screening to identify CRAB carriers before surgery. This should be integrated within diagnostic and antibiotic stewardship guidance, and the choice of targeted versus universal",
                "1. Clinical trials comparing the incidence risk of CRAB infections in carriers versus non-carriers, especially for patients undergoing high-risk surgery.\n        2. Trials investigating the efficacy and safety of targeted PAP in CRAB carriers undergoing SOT and other high-risk surgical procedures.\n        3. Trials considering rectal culture results for targeted PAP.\n        4. Trials taking into account the limited number",
                "Based on current recommendations and expert opinion, the suggested duration of PAP in transplant surgery other than renal transplant is 24-48 hours. However, for intestinal/multivisceral and lung transplantation, the duration may be extended up to 48-72 hours depending on the specific circumstances of the procedure. (References: 5,18,62)",
                "The risk of MDR-GNB infections in SOT recipients ranges from 3% to 53%, with highest rates observed for intestinal, liver, and pancreas transplantation. Intra-abdominal infections, particularly in the early post-transplant period, pose a significant risk for ESCR-E and CRKP infections. Post-SOT infections caused by MDR-GNB are associated with higher mortality",
                "1. Evaluate local resistance patterns to fluoroquinolones, particularly with E. coli, to help guide PAP selection.\n2. Consider rectal carriage rates of FQR-E and the associated risk of post-TRUSPB infectious complications.\n3. Use entrapment, cefoxitin, or fosfomycin in PAP for FQR-E carriers undergoing TRUSPB to reduce the incidence of BSIs",
                "The trial reported a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate for patients receiving ciprofloxacin PAP versus culture-based PAP. FQR carriers had a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers. However, the study did not demonstrate",
                "There is limited evidence on the impact of targeted preoperative antibiotic prophylaxis (PAP) on infectious complications following urologic surgery in MDR-GNB carriers. While urinary cultures are often obtained to treat asymptomatic bacteriuria before surgery, the optimal targeted PAP for different MDR-GNB and the effect on postoperative infections require further research. Eleven percent of patients receiving targeted PAP developed postoperative in",
                "A comprehensive approach to reducing SSIs involves a combination of antibiotic-based interventions and best surgical practices. This includes minimizing surgical operative time, regulating glucose and temperature, optimizing sterile techniques, managing patient comorbidities, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach. Additionally, targeted PAP for MDR-GNB carriers, especially in areas with high burden and",
                "1. For sampling site technique, it is recommended to follow evidence-based protocols, including the use of sterile equipment and proper aseptic technique to minimize contamination (ungraded good practice statement).\n        2. For microbiological methods, it is essential to use validated and standardized techniques for the detection and identification of carbapenem-resistant Acinetobacter baumannii (CRAB) and other multidrug-resistant gram-negative bacteria",
                "1. The type of solid organ transplant (SOT) and the associated risk of infections.\n2. The presence of ongoing infections and the need for adjusting PAP accordingly.\n3. The availability of data on adverse events and emergence of antibiotic resistance following targeted PAP.\n4. The specific CRE strain and its susceptibility pattern.\n5. The local epidemiology of CRE infections and the incidence of CRE SSIs",
                "It is important to know the colonization status of a patient before solid organ transplantation (SOT) to implement infection control procedures early and reduce the risk of intrahospital and community spreading of multidrug-resistant gram-negative bacteria (MDR-GNB), including carbapenem-resistant Enterobacterales (CRE) and XDRPA. This information can inform contact precautions and guide antibiotic and diagnostic stewardship."
            ]
        },
        "metrics": {
            "no additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.10426927455870987,
                    "2_gram": 0.17232945312043874,
                    "3_gram": 0.12203449066382968,
                    "4_gram": 0.08598788681468703
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.23668217296509428,
                        "recall": 0.4109030657231275,
                        "fmeasure": 0.285740394312968
                    },
                    "rouge_L": {
                        "precision": 0.15572278316466392,
                        "recall": 0.2809290035071148,
                        "fmeasure": 0.1908752053324701
                    }
                },
                "METEOR": 0.23717818182947348,
                "BERTScore": {
                    "Precision": -0.003,
                    "Recall": 0.171,
                    "F1_measure": 0.083
                }
            },
            "additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.11141463788088923,
                    "2_gram": 0.18204904662284616,
                    "3_gram": 0.13031715085607568,
                    "4_gram": 0.09079129596816363
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.24730519574032211,
                        "recall": 0.4196049847717524,
                        "fmeasure": 0.2914223958282858
                    },
                    "rouge_L": {
                        "precision": 0.17372168561673687,
                        "recall": 0.2921140135388925,
                        "fmeasure": 0.2044809352091253
                    }
                },
                "METEOR": 0.2426199338470025,
                "BERTScore": {
                    "Precision": 0.04,
                    "Recall": 0.216,
                    "F1_measure": 0.127
                }
            },
            "no additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.1148943737409432,
                    "2_gram": 0.2102630010212369,
                    "3_gram": 0.1952294635086596,
                    "4_gram": 0.15644496361953142
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.37140063206756685,
                        "recall": 0.6574005436574546,
                        "fmeasure": 0.4526537579506882
                    },
                    "rouge_L": {
                        "precision": 0.28791025333200226,
                        "recall": 0.5131767263041545,
                        "fmeasure": 0.35271610515631857
                    }
                },
                "METEOR": 0.45417970361736537,
                "BERTScore": {
                    "Precision": 0.228,
                    "Recall": 0.454,
                    "F1_measure": 0.338
                }
            },
            "additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.12082910645207444,
                    "2_gram": 0.22002930937115833,
                    "3_gram": 0.20387472494787223,
                    "4_gram": 0.16347821028759096
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.39589038469999416,
                        "recall": 0.6623833152796974,
                        "fmeasure": 0.46988349641550436
                    },
                    "rouge_L": {
                        "precision": 0.3185184185043962,
                        "recall": 0.527637902963698,
                        "fmeasure": 0.3770171122598627
                    }
                },
                "METEOR": 0.4644852186752972,
                "BERTScore": {
                    "Precision": 0.266,
                    "Recall": 0.478,
                    "F1_measure": 0.368
                }
            }
        }
    },
    {
        "parameters": {
            "embedding model": "BAAI/bge-small-en-v1.5",
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",
            "splitting method": "From scratch with Faiss vector store and SYNTACTIC splitter",
            "chunk size": 256,
            "overlap": 25,
            "top_k": 10,
            "max new tokens": 100,
            "re-ranking": 0,
            "top_n": 4
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What was the finding of the studies evaluating quinolones as a treatment option for 3GCephRE BSI?",
            "What was the finding of the studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE?",
            "What was the finding of the RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE?",
            "What is the level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible CRE?",
            "What is the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI?",
            "Is there sufficient evidence on plazomicin compared to colistin for the treatment of CRE infections?",
            "Is there a difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections?",
            "What is the evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections?",
            "What were the results of the retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections?",
            "What is the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin?",
            "What is the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP?",
            "What is the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections?",
            "What is the evidence from observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections?",
            "What are the general principles for antibiotic treatment in patients with CR-GNB infections?",
            "What is the suggested screening approach for patients undergoing colorectal and liver transplant surgery?",
            "What is the recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E undergoing colorectal surgery?",
            "What antibiotics should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers?",
            "What is recommended to be included in research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates?",
            "Can a recommendation be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery?",
            "What is a good practice for screening SOT recipients for CRAB before surgery?",
            "What type of clinical trials does the panel suggest designing to investigate CRAB colonization and targeted PAP?",
            "In transplant surgery other than renal transplant, what is the suggested duration of PAP?",
            "What is the risk of MDR-GNB infections in solid organ transplant (SOT) recipients, and what are the associated consequences?",
            "What is the suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB)?",
            "What is the outcome of a randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, particularly in fluoroquinolone-resistant (FQR) carriers?",
            "What is the association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery?",
            "What is the comprehensive approach required to reduce surgical site infections (SSIs)?",
            "What is recommended for standard operating procedures related to sampling site technique and microbiological methods?",
            "What should be considered when choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections?",
            "Why is it important to know the colonization status of a patient before solid organ transplantation (SOT)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "The studies found limited evidence on targeted quinolone therapy for 3GCephRE BSI, with one study reporting an association between quinolone treatment and lower mortality, but the analysis was limited by small sample sizes and potential biases, and therefore, there is no direct evidence to support the use of quinolones for targeted therapy.",
            "The studies, all of which were retrospective cohort studies with small sample sizes and high risk of bias, found no statistically significant differences between cephamycins and cefepime compared to carbapenems, providing low-certainty evidence for the use of cephamycins and cefepime in the treatment of pyelonephritis caused by 3GCephRE.",
            "The studies found that clinical or microbiological outcomes were similar between groups in all studies, with moderate certainty of evidence for ceftazidime-avibactam and very low certainty of evidence for eravacycline and ceftolozane-tazobactam in the treatment of IAI caused by 3GCephRE, although the trials were not powered to prove non-inferiority in these subgroups.",
            "There is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE, based on a small RCT (Tango-II) that showed significantly improved cure rates and non-significantly lower 28-day mortality.",
            "The level of evidence is moderate, based on several studies that showed better clinical outcomes, microbiological cure, and survival rates with aminoglycoside-containing regimens compared to tigecycline-containing regimens for cUTI.",
            "No, there is insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections, due to the suspension of the CARE-RCT study and limited available results.",
            "No, subgroup analysis of two RCTs (AIDA and OVERCOME) did not show statistically significant differences in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections.",
            "According to the CREDIBLE RCT, clinical and microbiological cure rates were similar between patients receiving cefiderocol monotherapy and combination therapy, but mortality data were not available and results were not presented separately for CRE.",
            "The study found that clinical cure was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam, but the study had a high risk of bias due to patient selection, baseline differences, and lack of data on carbapenem resistance.",
            "We suggest treatment with two in vitro active drugs (conditional recommendation for use, very low certainty of evidence), but no specific combination is recommended.",
            "We suggest ampicillin-sulbactam (conditional recommendation, low certainty of evidence).",
            "The available data suggest that cefiderocol does not have an advantage over other antibiotics, such as best available therapy (BAT) or high-dose extended-infusion meropenem, in terms of mortality, clinical, or microbiological outcomes in treating CRAB infections, and the evidence is of low certainty.",
            "Some observational studies suggest a significant association between polymyxin-carbapenem combination therapy and improved survival or clinical cure, while others do not; however, these studies are limited by their design and inability to assess the effects of specific combination regimens.",
            "The general principles include using optimal antibiotic dosing schemes, with attention to adverse effects, optimizing dosing and mode of administration by pathogen and indication, using therapeutic drug monitoring when available, prioritizing source control, and considering follow-up cultures in case of treatment failure to detect resistance development. Additionally, testing against new BLBLI and polymyxins is recommended for CR-GNB resistant to all blactams, and selecting antibiotic treatment with the least resistant antibiotic/s based on MICs relative to the breakpoints is recommended for pan-resistant CR-GNB.",
            "Rectal screening to identify ESCR-E carriers before surgery, taking into account local epidemiology.",
            "Targeted PAP is conditionally recommended in patients colonized with ESCR-E undergoing colorectal surgery, based on low certainty of evidence.",
            "Novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers.",
            "Research protocols should include postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used, and report antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.",
            "No, there is insufficient evidence for or against targeted PAP for patients colonized with CRE before surgery, and therefore no recommendation can be issued.",
            "It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRAB before surgery.",
            "The panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery, and investigating the efficacy of targeted versus routine PAP in CRAB carriers.",
            "The extension of PAP duration to 48-72 hours may be considered according to the type of transplant.",
            "SOT recipients are at high risk of MDR-GNB infections, with rates ranging from 3% to 53% depending on the type of transplant, and are associated with higher mortality compared to susceptible counterparts.",
            "Rectal screening is suggested to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
            "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate, with FQR carriers having a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers.",
            "Higher rates of postoperative infections, mainly surgical site infections (SSIs), were reported in patients with urinary colonization, particularly in ESCR-E carriers, with 31% developing postoperative infections, and 80% of these caused by the same colonizing strain.",
            "A comprehensive approach to reduce SSIs requires a combination of antibiotic-based interventions, such as targeted perioperative antibiotic prophylaxis (PAP), and best surgical practices, including minimization of surgical operative time, regulation of glucose and temperature, optimization of sterile techniques, and management of patient comorbidities, as well as heightening stewardship initiatives, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach.",
            "Standard operating procedures should be agreed upon according to national indications and evidence-based institutional protocols, including sampling site technique and microbiological methods.",
            "The choice of targeted PAP should take into consideration the limited number of options available for treating CRE infections, and avoid using novel compounds that may be needed for treating postsurgical infections.",
            "Knowing the colonization status before SOT is essential for the early implementation of infection control procedures, such as reducing the risk of intra-hospital and community spreading."
        ],
        "predicted answers": {
            "no additional prompt / no context": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-resistant Enterobacterales, or 3GCephrasporin-resistant K. pneumoniae, 3GCephraspor",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized",
                "Several studies have evaluated the use of quinolones as a treatment option for 3rd generation cephalosporin-resistant bloodstream infections (3GCephRE BSIs). Here are some key findings from these studies:\n\n1. Quinolones are effective against 3GCephRE BSIs caused by common pathogens such as Enterococcus faecium, Pseudomonas aeruginosa, and Klebsiella pneum",
                "Several studies have compared the effectiveness and safety of cephamycins (cefotetan and ceftriaxone), cefepime, and carbapenems (imipenem and meropenem) for the treatment of pyelonephritis caused by extended-spectrum \u03b2-lactamase producing Enterobacteriaceae (3GCephre).\n\nA systematic review and meta-analysis of 12 randomized controlled trials (",
                "Several randomized controlled trials (RCTs) have evaluated the effectiveness of various antibiotics for the treatment of intra-abdominal infections (IAIs) caused by third-generation cephalosporin-resistant Enterobacterales (3GCRE). Here are some key findings from these studies:\n\n1. Carbapenems: Carbapenems, such as imipenem, meropenem, and ertapen",
                "Meropenem-vaborbactam (MVB) is a carbapenem-beta-lactamase inhibitor combination antibiotic that has shown activity against certain carbapenem-resistant Enterobacterales (CRE), including those producing NDM-1 and OXA-48-type carbapenemases. The advantage of MVB over best available treatment for susceptible CRE is supported by several studies with varying levels of evidence",
                "The comparative effectiveness and safety of aminoglycosides versus tigecycline for the treatment of complicated urinary tract infections (cUTI), including uncomplicated cUTI, have been studied in several randomized controlled trials (RCTs) and meta-analyses.\n\nA systematic review and meta-analysis of 11 RCTs involving 3,512 patients published in the Cochrane Database of Systematic Reviews in",
                "Plazomicin and colistin are both antibiotics used in the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), but the evidence comparing the two drugs in terms of efficacy, safety, and optimal use is still evolving.\n\nPlazomicin is a new generation aminoglycoside with improved activity against CRE compared to older aminoglycosides. A phase 3 clinical trial,",
                "Several studies have investigated the difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with infections caused by Carbapenem-resistant Enterobacterales (CRE), including those caused by Klebsiella pneumoniae and other Enterobacterales. The results of these studies have been inconsistent.\n\nSome studies have reported no significant difference in 28-day mortality",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE), including Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa. The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is still emerging, and the optimal approach is not yet fully established.",
                "I apologize for any confusion, but I cannot provide you with the specific results of a retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections as there seems to be no published study with that exact title and inclusion criteria.\n\nHowever, there have been several studies investigating the effectiveness and safety of ceft",
                "CRPA (Carbapenem-resistant Pseudomonas aeruginosa) infections can be challenging to treat due to the resistance of the bacteria to many antibiotics. Polymyxins, aminoglycosides, and fosfomycin are commonly used antibiotics for the treatment of CRPA infections.\n\nPolymyxins, such as polymyxin B and E, are considered the first-line antibiot",
                "For patients with CRAB (Clostridioides difficile-related complications, including severe colitis, fulminant colitis, toxic megacolon, and sepsis) who are susceptible to sulbactam and have healthcare-associated pneumonia (HAP) or ventilator-associated pneumonia (VAP), the suggested treatment may depend on the severity of the infection and the patient's overall condition.\n\nFirst",
                "Cefiderocol is a siderophore cephalosporin antibiotic that is approved for the treatment of complicated intra-abdominal infections, including those caused by susceptible Gram-negative bacteria. CRAB (community-acquired or nosocomial acquisition, recurrent or persistent, intra-abdominal infections) is a specific type of intra-abdominal infection.\n\nSeveral studies have evaluated the effic",
                "Polymyxin-carbapenem combination therapy has been studied as a potential treatment option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections based on the synergistic effect of both antibiotics. However, the evidence from observational studies on the effectiveness of this combination therapy is limited and often inconsistent.\n\nOne study published in the Journal of Antimicrobial Chemotherapy in 201",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections are a significant challenge in clinical microbiology due to the increasing resistance of these bacteria to commonly used antibiotics. Here are some general principles for antibiotic treatment in patients with CR-GNB infections:\n\n1. Identify the specific CR-GNB causing the infection through microbiological culture and susceptibility testing. This information is crucial for selecting the most effective antibi",
                "Patients undergoing colorectal and liver transplant surgery require careful preoperative evaluation due to the complex nature of these procedures and the potential for complications. Here are some suggested screening approaches for these patients:\n\n1. Colorectal Transplant Surgery:\n- Preoperative assessment should include a thorough history and physical examination, with a focus on the gastrointestinal system.\n- Laboratory tests: Complete blood count, coagulation studies, electro",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Resistive-Escherichia coli (ESCR-E) undergoing colorectal surgery is not well-defined due to a lack of clear consensus in the literature. However, some guidelines suggest considering PAP based on the risk of surgical site infection (SSI) and the specific characteristics of the patient and the organ",
                "Extensively drug-resistant Enterococci (ESCR-E) and extensively drug-resistant Pseudomonas aeruginosa (ESCR-PA) are bacteria that have developed resistance to most or all available antibiotics. The treatment of infections caused by these bacteria is a challenge, and the use of last-resort antibiotics should be reserved for specific cases.\n\nThe European Society of Clinical Microbiology and Infectious Dise",
                "Research protocols investigating the impact of targeted PAP (pneumococcal and other encapsulated bacteria prevention using antibiotics) in reducing post-transplant infections among Extended-Spectrum Cephalosporin Resistant-Enterococcus (ESCR-E) colonized Solid Organ Transplant (SOT) candidates should include the following elements:\n\n1. Study Design: Clearly define the study design, including the type of study (",
                "Yes, a recommendation can be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery. The goal of PAP is to reduce the risk of surgical site infections (SSIs). In patients colonized with CRE, the risk of developing SSIs is increased due to the potential for carrying antibiotic-resistant bacteria. Therefore, targeted",
                "Screening SOT (solid organ transplant) recipients for CRAB (chronic rejection, acute rejection, banff lesions) before surgery involves a comprehensive evaluation to assess the current status of the transplanted organ and the overall health of the recipient. Here are some good practices for screening SOT recipients for CRAB before surgery:\n\n1. Review of medical history: A thorough review of the recipient's medical history, including details of the transplant procedure",
                "To investigate CRAB (Candida auris-related bloodstream infections) colonization and targeted PAP (positive blood culture identification and antimicrobial stewardship), the following types of clinical trials could be suggested:\n\n1. Prospective observational studies: These studies can be used to assess the prevalence and incidence of CRAB colonization in different patient populations and settings. They can also evaluate the effectiveness of targeted PAP in identifying CRAB in",
                "In transplant surgery other than renal transplants, the suggested duration of post-anesthesia care unit (PACU) or post-operative recovery varies depending on the specific type of transplant and the individual patient's condition. Here are some general guidelines for different types of transplants:\n\n1. Liver transplant: Patients typically stay in the PACU for 1-2 days after the surgery. However, some patients may require a longer",
                "MDR-GNB (Multidrug-resistant Gram-negative bacteria) infections are a significant concern in solid organ transplant (SOT) recipients due to their increased susceptibility to infections and the potential for antibiotic resistance. The risk of MDR-GNB infections in SOT recipients varies depending on several factors, including the type of transplant, the underlying condition of the patient, and the exposure to healthcare environments.\n\nAccording to a",
                "The identification of fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) is important to reduce the risk of post-biopsy infections and potential development of antibiotic-resistant bacteria. Here are some suggested approaches to identify FQR-E carriers:\n\n1. Pre-biopsy urine culture: Ob",
                "A randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP (Prostate Antigen Percentage using ciprofloxacin as a urinary selective inhibitor of bacterial growth) and culture-based PSA (Prostate Specific Antigen) in patients undergoing Transrectal Ultrasound-Guided Prostate Biopsy (TRUSPB) would provide data on the diagnostic accuracy and utility",
                "Urinary colonization with MDR-GNB has been identified as a risk factor for postoperative infections in patients undergoing urologic surgery. The presence of MDR-GNB in the urine before surgery increases the likelihood of developing postoperative infections, particularly urinary tract infections (UTIs).\n\nStudies have shown that the incidence of urinary colonization with MDR-GNB is higher in patients undergoing urologic surgery compared to",
                "Reducing surgical site infections (SSIs) requires a comprehensive approach that addresses various factors before, during, and after surgery. Here are some key elements of a comprehensive approach to reducing SSIs:\n\n1. Preoperative preparation:\n   a. Proper patient selection and optimization\n   b. Timely and appropriate antibiotic prophylaxis\n   c. Controlling risk factors such as diabetes, obesity, and malnutrition\n   d.",
                "Standard Operating Procedures (SOPs) for sampling site techniques and microbiological methods are essential to ensure consistency, accuracy, and reliability of data obtained from environmental or laboratory investigations. Here are some recommended practices for developing SOPs in these areas:\n\n1. Sampling Site Techniques:\n\na. Define the sampling objectives, location, and frequency.\nb. Establish a chain of custody for samples to maintain their integrity from the time of collection to",
                "When choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections, several factors should be considered to optimize the effectiveness of the antibiotic prophylaxis and minimize the risk of selecting for antibiotic resistance or causing adverse effects. Some of these factors include:\n\n1. Timing of administration: PAP should be administered within one hour before the surg",
                "Colonization status refers to the presence of potentially harmful bacteria in the body, particularly in the gastrointestinal tract, that do not cause infection in a healthy individual but can cause infections after a solid organ transplantation (SOT). These infections, known as translocation infections, can lead to significant morbidity and mortality in transplant recipients.\n\nThe importance of knowing the colonization status of a patient before SOT lies in the fact that certain"
            ],
            "additional prompt / no context": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum \u03b2-lactamase producing Klebsiella pneumoniae (3GCephrasporin-resistant, or 3GCephrE), the recommended targeted therapy is usually a carbapenem antibiotic, such as meropenem or imipenem. Other options may include polymyxins or aminocoumarins,",
                "The evidence on the treatment of infections caused by third-generation cephalosporin-resistant bacteria (3GCRE) is organized through numerous studies, meta-analyses, and guidelines. These sources provide evidence on the effectiveness and safety of various antibiotics, including carbapenems, aminoglycosides, and polymyxins, among others. The Infectious Diseases Society of America (IDSA) and European Society of Clin",
                "Quinolones have shown effectiveness in treating 3GCephalosporin-resistant bloodstream infections (BSIs). However, resistance to quinolones is increasing, so their use should be reserved for infections caused by susceptible bacteria. Adverse effects, including peripheral neuropathy and tendinitis, should be monitored closely.",
                "The studies suggest that cephamycins and cefepime are comparable to carbapenems in terms of clinical cure rates for pyelonephritis caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE). However, higher resistance rates to cephamycins and cefepime may require larger doses or alternative agents.",
                "The RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3rd-generation cephalosporin-resistant (3GCephR) bacteria have shown that:\n\n1. Carbapenems (imipenem, meropenem) are effective in treating 3GCephR-IAI.\n2. Aminoglycosides (gentamicin,",
                "The level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible Carbapenem-resistant Enterobacterales (CRE) is high, based on numerous randomized controlled trials and meta-analyses demonstrating superior clinical response and microbiological eradication rates.",
                "The evidence for the advantage of aminoglycosides over tigecycline for complicated urinary tract infections (cUTI) is inconclusive. Some studies suggest that aminoglycosides may have similar efficacy to tigecycline, while others suggest that tigecycline may have a slightly better safety profile. Ultimately, the choice between these antibiotics depends on individual patient factors and clinician preference.",
                "Plazomicin, a new antibiotic, has shown promise in clinical trials for the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), including those that are resistant to colistin. However, more data from larger, randomized controlled trials are needed to definitively establish the superiority of plazomicin over colistin in terms of clinical outcomes, safety, and resistance development. Therefore, the evidence is not yet sufficient",
                "Yes, there are studies suggesting that colistin-carbapenem combination therapy may have a lower 28-day mortality rate compared to colistin monotherapy in patients with Carbapenem-resistant Enterobacteriaceae (CRE) infections. However, the evidence is not definitive, and more research is needed to confirm these findings. It's important to note that individual patient outcomes can vary significantly based on factors such as underlying health conditions and",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE). The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections comes from several clinical studies.\n\nA randomized controlled trial (RCT) by Bekas et al. (2019) showed that monotherapy with cefiderocol led to similar",
                "The retrospective cohort study found that ceftolozane-tazobactam was associated with a higher clinical cure rate (83.3%) compared to polymyxins or aminoglycosides (63.6%) in patients with MDR/XDR P. aeruginosa mixed infections. However, it's important to note that retrospective studies have limitations, and more well-designed studies are needed to confirm these",
                "For severe infections caused by CRPA (Carbapenem-resistant Pseudomonas aeruginosa), the recommended antibiotic regimens include:\n\n1. Polymyxins (e.g., polymyxin B or E) in combination with an aminoglycoside (e.g., gentamicin or tobramycin).\n2. Monotherapy with a newer polymyxin (e.g",
                "For patients with CRAB (Carbapenem-resistant Acinetobacter baumannii) and susceptible to sulbactam but resistant to other antibiotics in the setting of HAP (Healthcare-associated pneumonia) or VAP (Ventilator-associated pneumonia), the suggested treatment options may include:\n\n1. Polymyxins (e.g., colistin or polymyxin",
                "Cefiderocol is an antibiotic with activity against gram-negative bacteria, including those commonly responsible for CRAB (community-acquired or healthcare-associated carbapenem-resistant acinetobacter baumannii) infections. Several studies have shown that cefiderocol is effective in treating CRAB infections, with success rates similar to or superior to other antibiotics such as colistin and tigecycline. However, it",
                "Observational studies suggest that polymyxin-carbapenem combination therapy may be effective in treating CRAB (Carbapenem-resistant Acinetobacter baumannii) infections. However, high-quality randomized controlled trials are needed to provide stronger evidence of its efficacy and safety. The combination therapy may improve outcomes by synergistic effects of both antibiotics against carbapenem-resistant A. baumannii.",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections require specific antibiotic treatment due to their resistance to commonly used antibiotics. Here are some general principles for antibiotic treatment:\n\n1. Identify the specific CR-GNB causing the infection through laboratory testing.\n2. Choose an antibiotic that is active against the identified CR-GNB.\n3. Consider the site of infection, severity, and patient",
                "For patients undergoing colorectal transplant surgery, preoperative screening typically includes colonoscopy to assess for colon cancer or precancerous lesions. For liver transplant patients, screening may include hepatitis serology, imaging studies like ultrasound or CT scan, and tumor markers like AFP. The specific screening approach may vary depending on individual patient risk factors and transplant type. Always consult with a healthcare professional for personalized medical advice.",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Cephalosporin-Resistant Enterococci (ESCR-E) undergoing colorectal surgery is controversial. Some guidelines suggest considering alternative antibiotics for PAP, while others recommend using a different class of antibiotics altogether, such as aminoglycosides or glycopeptides. Ultimately",
                "The antibiotics that should be reserved for the treatment of extensively resistant bacteria (such as extensively drug-resistant Mycobacterium tuberculosis or carbapenem-resistant Enterobacteriaceae) include:\n\n1. Polymyxins (e.g., colistin)\n2. Aminoglycosides (e.g., amikacin, gentamicin)\n3. Tigecycline",
                "Recommended components for research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates include:\n\n1. Study design: Randomized controlled trials (RCTs) or observational studies.\n2. Study population: ESCR-E colonized SOT candidates.\n3. Intervention: Targeted PAP (pre-transplant antimicrobial prophylaxis)",
                "Yes, a recommendation can be issued for targeted PAP for patients colonized with CRE before surgery to reduce the risk of surgical site infections caused by these bacteria. However, the specific antibiotic choice should be based on local resistance patterns and potential for cross-resistance. Consult local guidelines and infectious disease specialists for the most appropriate antibiotic selection.",
                "A good practice for screening Solid Organ Transplant (SOT) recipients for CRAB (Chronic Renal Allograft Abolition) before surgery is to assess their renal function with regular serum creatinine levels and estimated glomerular filtration rate (eGFR). Additionally, monitoring for proteinuria, hematuria, and signs of allograft dysfunction is essential. If there are concerns, a renal biopsy may be necessary",
                "To investigate CRAB (Clostridioides difficile-related antibiotic-associated bacterial) colonization and targeted PAP (phage-based antibiotic prophylaxis), the panel would suggest designing randomized controlled trials (RCTs) with a placebo or active comparator arm. These trials should include adequate sample size, proper power analysis, and appropriate endpoints to assess the efficacy and safety of targeted PAP in preventing CRAB colon",
                "In transplant surgery other than renal transplant, the suggested duration of post-operative positive airway pressure (PAP) varies depending on the specific type of transplant and individual patient's condition. Generally, it ranges from a few days to several weeks. For example, in liver transplant, PAP may be used for a few days to help prevent respiratory complications. In heart-lung transplant, PAP may be required for several weeks to help the",
                "The risk of Multidrug-resistant Gram-negative bacterial (MDR-GNB) infections in solid organ transplant (SOT) recipients is relatively high due to the use of immunosuppressive medications. These infections can lead to serious complications such as sepsis, organ failure, and increased mortality. Common MDR-GNB pathogens include P. aeruginosa, Acinetobacter baumannii, and Kle",
                "The suggested approach to identify FQR-E carriers before TRUSPB includes:\n\n1. Obtaining a urine culture before the procedure.\n2. Sensitivity testing for fluoroquinolones in the urine culture result.\n3. Considering alternative antibiotics for prophylaxis if FQR-E is identified.\n\nIt's important to note that the decision to test for FQR-E should be based on local",
                "The specific outcome of the trial you're referring to is not readily available in a clear and short answer format, as I would need to access the study's results to provide an accurate response. However, in general, non-blinded trials may be subject to bias, and comparing ciprofloxacin PAP (prostate antimicrobial prostatease) to culture-based PAP (transrectal ultrasound-guided prostate bi",
                "Urinary colonization with MDR-GNB is a significant risk factor for postoperative infections in patients undergoing urologic surgery. These bacteria can cause infections during or after the procedure, leading to increased morbidity and mortality. Preoperative urine screening and appropriate antibiotic prophylaxis can help reduce the risk of these infections.",
                "A comprehensive approach to reducing surgical site infections (SSIs) includes:\n\n1. Preoperative preparation: Optimizing the patient's health, proper wound preparation, and prophylactic antibiotics.\n2. Intraoperative measures: Sterile environment, proper surgical technique, and use of sterile instruments.\n3. Postoperative care: Wound care, early ambulation, and appropriate use of drains and dressings.\n4.",
                "For standard operating procedures (SOPs) related to sampling site technique, it's important to follow these steps:\n\n1. Properly clean and prepare the sampling site.\n2. Use sterile equipment for sampling.\n3. Collect sufficient sample size.\n4. Transport samples to the lab in appropriate containers and at proper temperature.\n\nFor microbiological methods, SOPs should include:\n\n1. Properly handling and transporting samples.",
                "When choosing targeted PAP for CRE infections, consider the following factors:\n\n1. Type and location of the surgery: The risk of surgical site infection (SSI) varies depending on the type and location of the surgery.\n2. Patient risk factors: Factors such as age, comorbidities, and underlying conditions increase the risk of SSIs.\n3. Type and susceptibility of the CRE isolate: The specific type and susceptibility of",
                "Colonization of a patient with bacteria or other pathogens that can cause infections is important to consider before solid organ transplantation (SOT) because these infections can lead to graft failure, increased morbidity, and mortality. Immunosuppressive drugs used after transplantation can weaken the patient's immune system, making them more susceptible to infections. Knowing the colonization status allows healthcare providers to take appropriate measures to prevent or treat"
            ],
            "no additional prompt / context": [
                "Based on the context provided, a carbapenem (imipenem or meropenem) is recommended as targeted therapy for patients with BSI and severe infection due to 3GCephRE (strong recommendation for use, moderate certainty of evidence).",
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome: Bloodstream infections (BSI), complicated urinary tract infections (cUTI), pneumonia, and intra-abdominal infections (IAI). For each syndrome, studies are discussed in relation to specific antibiotic treatments and comparisons between different antibiotics. The evidence is also evaluated in terms of study design, sample size, bias, and certainty.",
                "The studies evaluating quinolones as a treatment option for 3GCephRE BSI were mostly retrospective cohort studies with very small sample sizes. In one study reporting an adjusted analysis, quinolone treatment was associated with lower mortality compared with carbapenems in a small group of patients (24 patients). However, there is no direct evidence on targeted quinolone therapy for 3GCephRE BSI, and the evidence for quin",
                "The studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE provided low-certainty evidence due to the high risk of bias in all studies and the lack of statistically significant differences between groups in very small sample sizes. None of the studies found a significant advantage of cephamycins or cefepime over carbapenems for the treatment of pyel",
                "The MERINO trial was a randomized controlled trial (RCT) that compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-resistant Escherichia coli and K. pneumoniae [16]. The study found that meropenem was non-inferior to piperacillin-tazobactam in terms of clinical",
                "Based on the small RCT (Tango-II) mentioned in the context, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam for susceptible CRE compared with the old antibiotics. However, it is important to note that the study included only 47 patients and the clinical efficacy against MBL and OXA-48 producers, which are common in CRE, was not tested. Therefore, more research",
                "The certainty of the evidence for an advantage of aminoglycosides over tigecycline for cUTI was judged as moderate, based on studies that showed better clinical cure and microbiological success with aminoglycosides compared with tigecycline for cUTI, but with large confidence intervals and a risk of bias. However, there is insufficient evidence for other comparisons and other sources of infection.",
                "Based on the context provided, there is currently insufficient evidence on the comparative efficacy and safety of plazomicin versus colistin for the treatment of CRE infections. The CRaCKle cohort study showed all-cause mortality at 28 days was lower with plazomicin combination therapy compared with colistin combination therapy, but the study was suspended after 2 years and the sample size was small for CRE infections specifically [1",
                "Based on the information provided in the context, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections in the AIDA and OVERCOME trials. However, it is important to note that these trials did not show a clear advantage of one treatment over the other, and more research is needed to determine the optimal approach for treating CRE infections",
                "Based on the available evidence, there is low-certainty evidence for the non-inferiority of ceftiderocol compared with other antibiotics for MBL-producing CRE infections. However, there is no direct evidence comparing ceftiderocol monotherapy versus combination therapy specifically for CRE infections.\n\n        In the CREDIBLE RCT, mortality was higher in the cefiderocol arm compared with BAT (mostly pol",
                "The retrospective cohort study compared the clinical care and nephrotoxicity of ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections. The study found higher clinical care (adjusted OR 2.63, 95% CI 1.31-5.30) and lower nephroto",
                "The recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin is to use two in vitro active drugs (conditional recommendation for use, very low certainty of evidence). No specific combinations can be recommended or against.",
                "Based on the context provided, the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP is ampicillin-sublactam. This is a conditional recommendation with low certainty of evidence.",
                "Based on the available evidence, the data on the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections is of low certainty. The CREDIBLE-CR trial, which included mostly patients with HAP/VAP and BSI, showed higher mortality in the cefiderocol arm at 28 days and at the end of follow-up, despite similar clinical and microbiological efficacies. A subgroup analysis",
                "Several observational studies have assessed the combination of polymyxins and carbapenems for CRAB infections, showing a significant association between the use of the combination and survival or clinical cure in some studies [198, 235, 247]. However, it is important to note that many of these studies included patients treated with a polymyxin-carbapenem combination in a larger group of patients treated with different combination therapies",
                "1. Antibiotic stewardship considerations are important in the treatment of CR-GNB infections, especially when using last resort antibiotics like colistin and the new BLBLI.\n2. Empiric antibiotic therapy should target CR-GNB infections in patients considered at high risk before pathogen identification.\n3. Achieving appropriate empirical antibiotic therapy for patients with infections due to CR-GNB and conserving last",
                "Based on the context provided, it is suggested to implement rectal screening to identify Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers before colorectal and liver transplant surgery, according to the local epidemiology (conditional recommendation, low certainty of evidence). It might also be a good practice to screen all SOT recipients for ESCR-E before surgery according to the local epidemiology",
                "Based on the available evidence, it is conditionally recommended to use targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery (low certainty of evidence). This recommendation is based on two studies, one of which is a multicenter, non-randomized, interventional study that showed a potential benefit of etapenem use in reducing postoperative infections in ESCR-E carriers undergoing colorectal surgery [",
                "According to antimicrobial stewardship considerations, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESC",
                "1. Postsurgical monitoring of antibiotic resistance: This includes CRE colonization through rectal cultures, especially if carbapenem-based PAP is used.\n        2. Reporting antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.\n        3. Considering the local burden of ESCR-E and patient-related risk factors for carrier status in the trial",
                "Based on the current evidence, there is insufficient evidence to recommend for or against targeted PAP for patients who are colonized with CRE before surgery. Therefore, no recommendation can be issued at this time. However, it is important to note that the knowledge of CRE colonization in high-risk patients, such as those receiving transplant surgery, is relevant for infection control purposes and for the adaptation of postsurgical empirical treatment. The panel recommends designing clinical trials to assess the",
                "It might be a good practice to screen all SOT recipients for CRAB before surgery according to the local epidemiology (ungraded good practice statement). This can help inform infection control measures and potentially influence the choice of empirical postoperative antibiotic therapy. However, the evidence for the benefit of targeted preoperative antimicrobial prophylaxis (PAP) in CRAB carriers is limited. Future clinical trials are recommended to evaluate the effectiveness, applicability",
                "1. Clinical trials comparing the incidence risk of CRAB infections in carriers versus non-carriers, especially for patients undergoing high-risk surgery.\n        2. Clinical trials investigating the efficacy of targeted versus routine PAP in CRAB carriers.\n        3. Trials of targeted PAP in CRE carriers undergoing SOT and other high-risk surgical procedures, considering rectal culture results, the limited number of options",
                "Based on current recommendations from the Infectious Diseases Society of America, American Society of Health-System Pharmacists, Surgical Infection Society, and Society for Healthcare Epidemiology of America (IDSA/ASHP/SIS/SHEA) and other international societies, the suggested duration of PAP in transplant surgery other than renal transplant is not explicitly stated. However, in some cases, extending the PAP duration to 48-",
                "Solid organ transplant (SOT) recipients are at risk for MDR-GNB infections due to prolonged hospitalization, invasive procedures, ICU admission, and broad-spectrum antibiotic treatment. The exact incidence of MDR-GNB infections in SOT recipients varies depending on the type of organ transplanted and the geographic area. For instance, intra-abdominal infections in liver transplant recipients (LTR",
                "Based on the evidence reviewed, it is suggested that rectal screening be performed to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence). This approach can help ensure that targeted PAP is used for patients who are colonized with FQR-E, potentially reducing the risk of post-TRUSPB infections. It is important to consider local epidemiology and individual risk factors when implementing this screening strategy.",
                "The recently published randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB included 1288 patients, 15.8% of whom were FQR carriers. The study showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-",
                "The available evidence suggests that urinary colonization with MDR-GNB is associated with an increased risk of postoperative infections in patients undergoing urologic surgery. However, studies comparing postoperative infections in MDR-GNB urinary carriers versus noncarriers are lacking. A small, prospective single-centre study reported that 15% of patients receiving targeted PAP based on urine cultures developed postoperative infections, compared with 5",
                "The comprehensive approach required to reduce surgical site infections (SSIs) involves a combination of antibiotic-based interventions and best surgical practices. Antibiotic-based interventions include targeted PAP, heightened stewardship initiatives to monitor and contain the consequences of new prescription patterns, enhanced surveillance protocols, and improved local adherence to guidelines. Best surgical practices include minimization of surgical operative time, regulation of glucose and temperature, optimization of",
                "Based on the context provided, it is recommended to follow evidence-based screening protocols for MDR-GNB (including Carbapenem-resistant Enterobacterales (CRE) and Carbapenem-resistant Acinetobacter baumannii (CRAB)) before surgery. The choice of targeted versus universal screening should be based on the local work organization and integrated within antibiotic and diagnostic stewardship guidance. Any change in procedures should consider the local",
                "1. Rectal culture results: Clinical trials of targeted PAP should consider rectal culture results to determine the most effective regimen for CRE carriers.\n        2. Limited treatment options: The choice of targeted PAP should take into consideration the limited number of options that are available for the treatment of CRE infections, avoiding novel compounds that may be required for the treatment of postsurgical inctions.\n        3. Resistance monitoring: Resistance monitoring should be performed",
                "Knowing the colonization status of a patient before solid organ transplantation (SOT) is essential for several reasons. First, it allows for the early implementation of infection control procedures to reduce the risk of intra-hospital and community spreading. Second, it is relevant for the adaption of postsurgical empirical treatment, especially in high-risk patients such as those receiving transplant surgery. Lastly, there is emerging evidence that colonization with certain multidrug-res"
            ],
            "additional prompt / context": [
                "A carbapenem (imipenem or meropenem) is recommended for patients with BSI and severe infection due to 3GCephRE as targeted therapy (strong recommendation for use, moderate certainty of evidence).",
                "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome: Bloodstream infections (BSI), complicated urinary tract infections (cUTI), pneumonia, and intra-abdominal infections (IAI). The studies assessing each syndrome are described in Table 3. For example, the evidence on BSI includes the MERINO trial comparing piperacillin-tazobactam with meropenem",
                "The studies evaluating quinolones as a treatment option for 3GCephRE BSI reported favorable effects in studies assessing Gram-negative bacteriaemia in general, but there is no direct evidence on targeted quinolone therapy for 3GCephRE BSI due to the small number of patients and the fact that quinolones were given as stepdown therapy to stable patients. The evidence for aminoglycoside treatment for bacteriaemic UTI is also",
                "All studies were at high risk of bias and none found statistically significant differences between cephamycins and cefepime and carbapenems for the treatment of pyelonephritis caused by 3GCephRE, providing low-certainty evidence.",
                "The MERINO trial was the only RCT specifically evaluating piperacillin-tazobactam versus meropenem for IAI caused by 3GCephRE [16]. The trial did not show a significant difference in mortality or other outcomes between the two antibiotics. However, the study was conducted over two decades ago and the results may not be directly applicable to current clinical practice due to advances in antibiotic resistance and treatment options.",
                "Based on the small RCT (Tango-II) mentioned in the context, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam for susceptible CRE compared with the old antibiotics.",
                "The certainty of the evidence for an advantage of aminoglycosides over tigecycline for cUTI is moderate. However, it is important to note that the evidence is insufficient for other comparisons and other sources of infection. The evidence includes studies demonstrating better clinical and microbiological response with aminoglycosides compared with tigecycline for cUTI caused by CRE, as well as studies showing higher survival rates with aminog",
                "Based on the context provided, there is currently insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections. The CRaCKle cohort studies suggest better clinical outcomes with aminoglycoside-containing regimens compared to tigecycline-containing regimens, but there is no direct comparison between plazomicin and colistin for CRE. Therefore, more research is needed to establish the compar",
                "Based on the available evidence from the AIDA and OVERCOME trials, there is no statistically significant difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections. However, it is important to note that the heterogeneity of treatment included in these studies makes it difficult to draw firm conclusions on which companion drug should be preferred when prescribing polymyxin and",
                "Based on the available evidence, there is very-low certainty for the non-inferiority of cefiderocol compared with other antibiotics for MBL-producing CRE, and no direct comparison studies have been conducted between cefiderocol monotherapy and combination therapy for CRE infections. Therefore, it is not possible to make a definitive recommendation for or against the use of cefiderocol monotherapy versus combination therapy in the treatment of CRE infections",
                "The retrospective cohort study reported higher clinical care (adjusted OR 2.63, 95% CI 1.31-5.30) and lower nephrotoxicity (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam compared with polymyxins or aminoglycosides",
                "The recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin is to use two in vitro active drugs (conditional recommendation for use, very low certainty of evidence). No specific combinations can be recommended or against.",
                "For patients with CRAB susceptible to sulbactam and HAP/VAP, the suggested treatment is ampicillin-sulbactam.",
                "Based on the available evidence, including the CREDIBLE-CR and APEKS-NP trials, there is low-certainty evidence for the non-inferiority of cefiderocol compared to other antibiotics for MBL-producing CRE infections. However, given the limited data, we cannot make a strong recommendation for or against the use of cefiderocol for CRAB infections.",
                "Several observational studies have shown an association between the use of polymyxin-carbapenem combination therapy and improved survival or clinical cure in CRAB infections. However, these studies did not specifically assess the effects of a polymyxin-carbapenem combination regimen, as they often included patients treated with various combination therapies. The RCT evidence, including the AIDA and OVERCOME trials, did not show statistically significant differences",
                "1. Antibiotic stewardship considerations are important when treating CR-GNB infections, especially when using last resort antibiotics like colistin and the new BLBLI.\n2. For CR-GNB that are resistant to all b-lactams, testing against the new BLBLI and polymyxins is recommended.\n3. Follow-up cultures are recommended in case of treatment failure, especially for CR-GNB, to",
                "Based on the context provided, it is suggested to implement rectal screening to identify Extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) carriers before colorectal and liver transplant surgery according to the local epidemiology (conditional recommendation, low certainty of evidence). It might also be a good practice to screen all SOT recipients for ESCR-E before surgery according to the local epidemiology (",
                "We conditionally recommend targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery (low certainty of evidence).",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers. Car",
                "1. Postsurgical monitoring of antibiotic resistance, specifically CRE colonization through rectal cultures, especially if carbapenem-based PAP is used.\n2. Reporting antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.\n3. Designing clinical trials in ESCR-E carriers undergoing high-risk surgical procedures, considering the local burden",
                "Based on the current evidence, no definitive recommendation can be issued for targeted PAP for patients who are colonized with CRE before surgery. While rectal screening for CRE carriers before liver transplant surgery is conditionally recommended according to local epidemiology, there is insufficient evidence to support targeted PAP for other types of surgery. Clinical trials are recommended to assess the impact of CRE rectal screening in high-risk surgeries and evaluate the effectiveness, applicability",
                "It might be a good practice to screen all SOT recipients for CRAB before surgery according to the local epidemiology. (ungraded good practice statement)",
                "1. Clinical trials comparing the incidence risk of CRAB infections in carriers versus non-carriers, especially for patients undergoing high-risk surgery.\n        2. Clinical trials investigating the efficacy of targeted versus routine PAP in CRAB carriers.\n        3. Trials considering rectal culture results for targeted PAP.\n        4. Trials taking into account the limited number of options for treating CRE infections, avoiding novel comp",
                "The suggested duration of PAP in transplant surgery other than renal transplant is 48-72 hours, according to some good practice statements. However, the optimal duration of targeted PAP in MDR-GNB carriers should align with current recommendations, which suggest discontinuation within 24 hours after surgery. Further research is needed to investigate the clinical impact of shorter versus longer PAP in patients undergoing transplant surgery.",
                "The risk of MDR-GNB infections in SOT recipients varies depending on the type of organ transplanted and the geographic area. SSIs are a common issue and may occur in 3% to 53% of SOT recipients, with highest rates observed for intestinal, liver, and pancreas transplantation. Among nonfermenters, rates of CRAB and MDR PA infections in bloodstream infections (BSIs)",
                "1. We suggest rectal screening to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).\n        2. For patients who are identified as FQR-E carriers, the use of targeted PAP is suggested during TRUSPB (conditional recommendation, moderate certainty of evidence).",
                "The recently published randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate for the culture-based PAP group. FQR carriers had a",
                "There is limited evidence on the impact of targeted preoperative antibiotic prophylaxis (PAP) on infectious complications following urologic surgery in MDR-GNB carriers. Higher rates of postoperative infections have been reported among patients with urinary colonization compared with noncolonized ones. However, studies comparing postoperative infections in MDR-GNB urinary carriers versus noncarriers are lacking. A small prospective study suggested",
                "The comprehensive approach to reduce SSIs requires a focus on both antibiotic-based interventions and best surgical practices. This includes minimizing surgical operative time, regulating glucose and temperature, optimizing sterile techniques, and managing patient comorbidities. Additionally, heightening stewardship initiatives to monitor and contain the consequences of new prescription patterns, enhance surveillance protocols, improve local adherence to guidelines, and promote a multidisciplinary approach are essential",
                "1. Standard operating procedures (SOPs) for sampling site technique and microbiological methods should be evidence-based and followed consistently to ensure accurate and reliable results.\n        2. Sampling site technique: Proper aseptic technique should be used when collecting samples to minimize contamination. This includes using sterile equipment, wearing appropriate personal protective equipment, and ensuring proper hand hygiene.\n        3. Microbiological methods: Standardized methods for culturing and identifying microorgan",
                "1. The limited number of options available for the treatment of CRE infections should be taken into consideration when choosing targeted PAP to avoid using novel compounds that may be required for the treatment of postsurgical infections.\n        2. Resistance monitoring should be performed through detection of MDR-CRE carriage after surgery and to detect emerging resistance to the regimens used for targeted PAP.\n        3. The clonal relationship between MDR bacteria detected after surgery and preoper",
                "It is important to know the colonization status of a patient before solid organ transplantation (SOT) because this information can inform infection control measures and help adapt post-surgical empirical treatment. Early detection of multidrug-resistant gram-negative bacteria (MDR-GNB) carriers can reduce the risk of intrahospital and community spreading. Limited evidence suggests that carriers of certain types of MDR-GNB, such as extended-spectrum cep"
            ]
        },
        "metrics": {
            "no additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.10426927455870987,
                    "2_gram": 0.17232945312043874,
                    "3_gram": 0.12203449066382968,
                    "4_gram": 0.08598788681468703
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.23668217296509428,
                        "recall": 0.4109030657231275,
                        "fmeasure": 0.285740394312968
                    },
                    "rouge_L": {
                        "precision": 0.15572278316466392,
                        "recall": 0.2809290035071148,
                        "fmeasure": 0.1908752053324701
                    }
                },
                "METEOR": 0.23717818182947348,
                "BERTScore": {
                    "Precision": -0.003,
                    "Recall": 0.171,
                    "F1_measure": 0.083
                }
            },
            "additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.11141463788088923,
                    "2_gram": 0.18204904662284616,
                    "3_gram": 0.13031715085607568,
                    "4_gram": 0.09079129596816363
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.24730519574032211,
                        "recall": 0.4196049847717524,
                        "fmeasure": 0.2914223958282858
                    },
                    "rouge_L": {
                        "precision": 0.17372168561673687,
                        "recall": 0.2921140135388925,
                        "fmeasure": 0.2044809352091253
                    }
                },
                "METEOR": 0.2426199338470025,
                "BERTScore": {
                    "Precision": 0.04,
                    "Recall": 0.216,
                    "F1_measure": 0.127
                }
            },
            "no additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.11415746039575414,
                    "2_gram": 0.21107187969386862,
                    "3_gram": 0.20241025965182308,
                    "4_gram": 0.16598972511460408
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.38647713394911154,
                        "recall": 0.7154479310221302,
                        "fmeasure": 0.47801629512691524
                    },
                    "rouge_L": {
                        "precision": 0.2961961275498334,
                        "recall": 0.5795083793361241,
                        "fmeasure": 0.37449273582930664
                    }
                },
                "METEOR": 0.48086150145693524,
                "BERTScore": {
                    "Precision": 0.247,
                    "Recall": 0.523,
                    "F1_measure": 0.381
                }
            },
            "additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.14080444140458698,
                    "2_gram": 0.2519420479626995,
                    "3_gram": 0.2443690426194727,
                    "4_gram": 0.20121191655465626
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.45997974183011536,
                        "recall": 0.6998493129606609,
                        "fmeasure": 0.5254668113079053
                    },
                    "rouge_L": {
                        "precision": 0.3739159860064431,
                        "recall": 0.5782968319232059,
                        "fmeasure": 0.4300256491592417
                    }
                },
                "METEOR": 0.5015651184236096,
                "BERTScore": {
                    "Precision": 0.331,
                    "Recall": 0.539,
                    "F1_measure": 0.432
                }
            }
        }
    },
    {
        "parameters": {
            "embedding model": "BAAI/bge-small-en-v1.5",
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",
            "splitting method": "From scratch with Faiss vector store and SYNTACTIC splitter",
            "chunk size": 256,
            "overlap": 25,
            "top_k": 10,
            "max new tokens": 100,
            "re-ranking": 1,
            "top_n": 4
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What was the finding of the studies evaluating quinolones as a treatment option for 3GCephRE BSI?",
            "What was the finding of the studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE?",
            "What was the finding of the RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE?",
            "What is the level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible CRE?",
            "What is the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI?",
            "Is there sufficient evidence on plazomicin compared to colistin for the treatment of CRE infections?",
            "Is there a difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections?",
            "What is the evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections?",
            "What were the results of the retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections?",
            "What is the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin?",
            "What is the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP?",
            "What is the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections?",
            "What is the evidence from observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections?",
            "What are the general principles for antibiotic treatment in patients with CR-GNB infections?",
            "What is the suggested screening approach for patients undergoing colorectal and liver transplant surgery?",
            "What is the recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E undergoing colorectal surgery?",
            "What antibiotics should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers?",
            "What is recommended to be included in research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates?",
            "Can a recommendation be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery?",
            "What is a good practice for screening SOT recipients for CRAB before surgery?",
            "What type of clinical trials does the panel suggest designing to investigate CRAB colonization and targeted PAP?",
            "In transplant surgery other than renal transplant, what is the suggested duration of PAP?",
            "What is the risk of MDR-GNB infections in solid organ transplant (SOT) recipients, and what are the associated consequences?",
            "What is the suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB)?",
            "What is the outcome of a randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, particularly in fluoroquinolone-resistant (FQR) carriers?",
            "What is the association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery?",
            "What is the comprehensive approach required to reduce surgical site infections (SSIs)?",
            "What is recommended for standard operating procedures related to sampling site technique and microbiological methods?",
            "What should be considered when choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections?",
            "Why is it important to know the colonization status of a patient before solid organ transplantation (SOT)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "The studies found limited evidence on targeted quinolone therapy for 3GCephRE BSI, with one study reporting an association between quinolone treatment and lower mortality, but the analysis was limited by small sample sizes and potential biases, and therefore, there is no direct evidence to support the use of quinolones for targeted therapy.",
            "The studies, all of which were retrospective cohort studies with small sample sizes and high risk of bias, found no statistically significant differences between cephamycins and cefepime compared to carbapenems, providing low-certainty evidence for the use of cephamycins and cefepime in the treatment of pyelonephritis caused by 3GCephRE.",
            "The studies found that clinical or microbiological outcomes were similar between groups in all studies, with moderate certainty of evidence for ceftazidime-avibactam and very low certainty of evidence for eravacycline and ceftolozane-tazobactam in the treatment of IAI caused by 3GCephRE, although the trials were not powered to prove non-inferiority in these subgroups.",
            "There is moderate-certainty evidence for an advantage of meropenem-vaborbactam over best available treatment for susceptible CRE, based on a small RCT (Tango-II) that showed significantly improved cure rates and non-significantly lower 28-day mortality.",
            "The level of evidence is moderate, based on several studies that showed better clinical outcomes, microbiological cure, and survival rates with aminoglycoside-containing regimens compared to tigecycline-containing regimens for cUTI.",
            "No, there is insufficient evidence on plazomicin compared to colistin for the treatment of CRE infections, due to the suspension of the CARE-RCT study and limited available results.",
            "No, subgroup analysis of two RCTs (AIDA and OVERCOME) did not show statistically significant differences in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections.",
            "According to the CREDIBLE RCT, clinical and microbiological cure rates were similar between patients receiving cefiderocol monotherapy and combination therapy, but mortality data were not available and results were not presented separately for CRE.",
            "The study found that clinical cure was higher (adjusted OR 2.63, 95% CI 1.31-5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03-0.22) with ceftolozane-tazobactam, but the study had a high risk of bias due to patient selection, baseline differences, and lack of data on carbapenem resistance.",
            "We suggest treatment with two in vitro active drugs (conditional recommendation for use, very low certainty of evidence), but no specific combination is recommended.",
            "We suggest ampicillin-sulbactam (conditional recommendation, low certainty of evidence).",
            "The available data suggest that cefiderocol does not have an advantage over other antibiotics, such as best available therapy (BAT) or high-dose extended-infusion meropenem, in terms of mortality, clinical, or microbiological outcomes in treating CRAB infections, and the evidence is of low certainty.",
            "Some observational studies suggest a significant association between polymyxin-carbapenem combination therapy and improved survival or clinical cure, while others do not; however, these studies are limited by their design and inability to assess the effects of specific combination regimens.",
            "The general principles include using optimal antibiotic dosing schemes, with attention to adverse effects, optimizing dosing and mode of administration by pathogen and indication, using therapeutic drug monitoring when available, prioritizing source control, and considering follow-up cultures in case of treatment failure to detect resistance development. Additionally, testing against new BLBLI and polymyxins is recommended for CR-GNB resistant to all blactams, and selecting antibiotic treatment with the least resistant antibiotic/s based on MICs relative to the breakpoints is recommended for pan-resistant CR-GNB.",
            "Rectal screening to identify ESCR-E carriers before surgery, taking into account local epidemiology.",
            "Targeted PAP is conditionally recommended in patients colonized with ESCR-E undergoing colorectal surgery, based on low certainty of evidence.",
            "Novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers.",
            "Research protocols should include postsurgical monitoring of antibiotic resistance, such as CRE colonization through rectal cultures, especially if carbapenem-based PAP is used, and report antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) results.",
            "No, there is insufficient evidence for or against targeted PAP for patients colonized with CRE before surgery, and therefore no recommendation can be issued.",
            "It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRAB before surgery.",
            "The panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery, and investigating the efficacy of targeted versus routine PAP in CRAB carriers.",
            "The extension of PAP duration to 48-72 hours may be considered according to the type of transplant.",
            "SOT recipients are at high risk of MDR-GNB infections, with rates ranging from 3% to 53% depending on the type of transplant, and are associated with higher mortality compared to susceptible counterparts.",
            "Rectal screening is suggested to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
            "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate, with FQR carriers having a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers.",
            "Higher rates of postoperative infections, mainly surgical site infections (SSIs), were reported in patients with urinary colonization, particularly in ESCR-E carriers, with 31% developing postoperative infections, and 80% of these caused by the same colonizing strain.",
            "A comprehensive approach to reduce SSIs requires a combination of antibiotic-based interventions, such as targeted perioperative antibiotic prophylaxis (PAP), and best surgical practices, including minimization of surgical operative time, regulation of glucose and temperature, optimization of sterile techniques, and management of patient comorbidities, as well as heightening stewardship initiatives, enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach.",
            "Standard operating procedures should be agreed upon according to national indications and evidence-based institutional protocols, including sampling site technique and microbiological methods.",
            "The choice of targeted PAP should take into consideration the limited number of options available for treating CRE infections, and avoid using novel compounds that may be needed for treating postsurgical infections.",
            "Knowing the colonization status before SOT is essential for the early implementation of infection control procedures, such as reducing the risk of intra-hospital and community spreading."
        ],
        "predicted answers": {
            "no additional prompt / no context": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-resistant Enterobacterales, or 3GCephrasporin-resistant K. pneumoniae, 3GCephraspor",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized",
                "Several studies have evaluated the use of quinolones as a treatment option for 3rd generation cephalosporin-resistant bloodstream infections (3GCephRE BSIs). Here are some key findings from these studies:\n\n1. Quinolones are effective against 3GCephRE BSIs caused by common pathogens such as Enterococcus faecium, Pseudomonas aeruginosa, and Klebsiella pneum",
                "Several studies have compared the effectiveness and safety of cephamycins (cefotetan and ceftriaxone), cefepime, and carbapenems (imipenem and meropenem) for the treatment of pyelonephritis caused by extended-spectrum \u03b2-lactamase producing Enterobacteriaceae (3GCephre).\n\nA systematic review and meta-analysis of 12 randomized controlled trials (",
                "Several randomized controlled trials (RCTs) have evaluated the effectiveness of various antibiotics for the treatment of intra-abdominal infections (IAIs) caused by third-generation cephalosporin-resistant Enterobacterales (3GCRE). Here are some key findings from these studies:\n\n1. Carbapenems: Carbapenems, such as imipenem, meropenem, and ertapen",
                "Meropenem-vaborbactam (MVB) is a carbapenem-beta-lactamase inhibitor combination antibiotic that has shown activity against certain carbapenem-resistant Enterobacterales (CRE), including those producing NDM-1 and OXA-48-type carbapenemases. The advantage of MVB over best available treatment for susceptible CRE is supported by several studies with varying levels of evidence",
                "The comparative effectiveness and safety of aminoglycosides versus tigecycline for the treatment of complicated urinary tract infections (cUTI), including uncomplicated cUTI, have been studied in several randomized controlled trials (RCTs) and meta-analyses.\n\nA systematic review and meta-analysis of 11 RCTs involving 3,512 patients published in the Cochrane Database of Systematic Reviews in",
                "Plazomicin and colistin are both antibiotics used in the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), but the evidence comparing the two drugs in terms of efficacy, safety, and optimal use is still evolving.\n\nPlazomicin is a new generation aminoglycoside with improved activity against CRE compared to older aminoglycosides. A phase 3 clinical trial,",
                "Several studies have investigated the difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with infections caused by Carbapenem-resistant Enterobacterales (CRE), including those caused by Klebsiella pneumoniae and other Enterobacterales. The results of these studies have been inconsistent.\n\nSome studies have reported no significant difference in 28-day mortality",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE), including Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa. The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections is still emerging, and the optimal approach is not yet fully established.",
                "I apologize for any confusion, but I cannot provide you with the specific results of a retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections as there seems to be no published study with that exact title and inclusion criteria.\n\nHowever, there have been several studies investigating the effectiveness and safety of ceft",
                "CRPA (Carbapenem-resistant Pseudomonas aeruginosa) infections can be challenging to treat due to the resistance of the bacteria to many antibiotics. Polymyxins, aminoglycosides, and fosfomycin are commonly used antibiotics for the treatment of CRPA infections.\n\nPolymyxins, such as polymyxin B and E, are considered the first-line antibiot",
                "For patients with CRAB (Clostridioides difficile-related complications, including severe colitis, fulminant colitis, toxic megacolon, and sepsis) who are susceptible to sulbactam and have healthcare-associated pneumonia (HAP) or ventilator-associated pneumonia (VAP), the suggested treatment may depend on the severity of the infection and the patient's overall condition.\n\nFirst",
                "Cefiderocol is a siderophore cephalosporin antibiotic that is approved for the treatment of complicated intra-abdominal infections, including those caused by susceptible Gram-negative bacteria. CRAB (community-acquired or nosocomial acquisition, recurrent or persistent, intra-abdominal infections) is a specific type of intra-abdominal infection.\n\nSeveral studies have evaluated the effic",
                "Polymyxin-carbapenem combination therapy has been studied as a potential treatment option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections based on the synergistic effect of both antibiotics. However, the evidence from observational studies on the effectiveness of this combination therapy is limited and often inconsistent.\n\nOne study published in the Journal of Antimicrobial Chemotherapy in 201",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections are a significant challenge in clinical microbiology due to the increasing resistance of these bacteria to commonly used antibiotics. Here are some general principles for antibiotic treatment in patients with CR-GNB infections:\n\n1. Identify the specific CR-GNB causing the infection through microbiological culture and susceptibility testing. This information is crucial for selecting the most effective antibi",
                "Patients undergoing colorectal and liver transplant surgery require careful preoperative evaluation due to the complex nature of these procedures and the potential for complications. Here are some suggested screening approaches for these patients:\n\n1. Colorectal Transplant Surgery:\n- Preoperative assessment should include a thorough history and physical examination, with a focus on the gastrointestinal system.\n- Laboratory tests: Complete blood count, coagulation studies, electro",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Resistive-Escherichia coli (ESCR-E) undergoing colorectal surgery is not well-defined due to a lack of clear consensus in the literature. However, some guidelines suggest considering PAP based on the risk of surgical site infection (SSI) and the specific characteristics of the patient and the organ",
                "Extensively drug-resistant Enterococci (ESCR-E) and extensively drug-resistant Pseudomonas aeruginosa (ESCR-PA) are bacteria that have developed resistance to most or all available antibiotics. The treatment of infections caused by these bacteria is a challenge, and the use of last-resort antibiotics should be reserved for specific cases.\n\nThe European Society of Clinical Microbiology and Infectious Dise",
                "Research protocols investigating the impact of targeted PAP (pneumococcal and other encapsulated bacteria prevention using antibiotics) in reducing post-transplant infections among Extended-Spectrum Cephalosporin Resistant-Enterococcus (ESCR-E) colonized Solid Organ Transplant (SOT) candidates should include the following elements:\n\n1. Study Design: Clearly define the study design, including the type of study (",
                "Yes, a recommendation can be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery. The goal of PAP is to reduce the risk of surgical site infections (SSIs). In patients colonized with CRE, the risk of developing SSIs is increased due to the potential for carrying antibiotic-resistant bacteria. Therefore, targeted",
                "Screening SOT (solid organ transplant) recipients for CRAB (chronic rejection, acute rejection, banff lesions) before surgery involves a comprehensive evaluation to assess the current status of the transplanted organ and the overall health of the recipient. Here are some good practices for screening SOT recipients for CRAB before surgery:\n\n1. Review of medical history: A thorough review of the recipient's medical history, including details of the transplant procedure",
                "To investigate CRAB (Candida auris-related bloodstream infections) colonization and targeted PAP (positive blood culture identification and antimicrobial stewardship), the following types of clinical trials could be suggested:\n\n1. Prospective observational studies: These studies can be used to assess the prevalence and incidence of CRAB colonization in different patient populations and settings. They can also evaluate the effectiveness of targeted PAP in identifying CRAB in",
                "In transplant surgery other than renal transplants, the suggested duration of post-anesthesia care unit (PACU) or post-operative recovery varies depending on the specific type of transplant and the individual patient's condition. Here are some general guidelines for different types of transplants:\n\n1. Liver transplant: Patients typically stay in the PACU for 1-2 days after the surgery. However, some patients may require a longer",
                "MDR-GNB (Multidrug-resistant Gram-negative bacteria) infections are a significant concern in solid organ transplant (SOT) recipients due to their increased susceptibility to infections and the potential for antibiotic resistance. The risk of MDR-GNB infections in SOT recipients varies depending on several factors, including the type of transplant, the underlying condition of the patient, and the exposure to healthcare environments.\n\nAccording to a",
                "The identification of fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB) is important to reduce the risk of post-biopsy infections and potential development of antibiotic-resistant bacteria. Here are some suggested approaches to identify FQR-E carriers:\n\n1. Pre-biopsy urine culture: Ob",
                "A randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP (Prostate Antigen Percentage using ciprofloxacin as a urinary selective inhibitor of bacterial growth) and culture-based PSA (Prostate Specific Antigen) in patients undergoing Transrectal Ultrasound-Guided Prostate Biopsy (TRUSPB) would provide data on the diagnostic accuracy and utility",
                "Urinary colonization with MDR-GNB has been identified as a risk factor for postoperative infections in patients undergoing urologic surgery. The presence of MDR-GNB in the urine before surgery increases the likelihood of developing postoperative infections, particularly urinary tract infections (UTIs).\n\nStudies have shown that the incidence of urinary colonization with MDR-GNB is higher in patients undergoing urologic surgery compared to",
                "Reducing surgical site infections (SSIs) requires a comprehensive approach that addresses various factors before, during, and after surgery. Here are some key elements of a comprehensive approach to reducing SSIs:\n\n1. Preoperative preparation:\n   a. Proper patient selection and optimization\n   b. Timely and appropriate antibiotic prophylaxis\n   c. Controlling risk factors such as diabetes, obesity, and malnutrition\n   d.",
                "Standard Operating Procedures (SOPs) for sampling site techniques and microbiological methods are essential to ensure consistency, accuracy, and reliability of data obtained from environmental or laboratory investigations. Here are some recommended practices for developing SOPs in these areas:\n\n1. Sampling Site Techniques:\n\na. Define the sampling objectives, location, and frequency.\nb. Establish a chain of custody for samples to maintain their integrity from the time of collection to",
                "When choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections, several factors should be considered to optimize the effectiveness of the antibiotic prophylaxis and minimize the risk of selecting for antibiotic resistance or causing adverse effects. Some of these factors include:\n\n1. Timing of administration: PAP should be administered within one hour before the surg",
                "Colonization status refers to the presence of potentially harmful bacteria in the body, particularly in the gastrointestinal tract, that do not cause infection in a healthy individual but can cause infections after a solid organ transplantation (SOT). These infections, known as translocation infections, can lead to significant morbidity and mortality in transplant recipients.\n\nThe importance of knowing the colonization status of a patient before SOT lies in the fact that certain"
            ],
            "additional prompt / no context": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum \u03b2-lactamase producing Klebsiella pneumoniae (3GCephrasporin-resistant, or 3GCephrE), the recommended targeted therapy is usually a carbapenem antibiotic, such as meropenem or imipenem. Other options may include polymyxins or aminocoumarins,",
                "The evidence on the treatment of infections caused by third-generation cephalosporin-resistant bacteria (3GCRE) is organized through numerous studies, meta-analyses, and guidelines. These sources provide evidence on the effectiveness and safety of various antibiotics, including carbapenems, aminoglycosides, and polymyxins, among others. The Infectious Diseases Society of America (IDSA) and European Society of Clin",
                "Quinolones have shown effectiveness in treating 3GCephalosporin-resistant bloodstream infections (BSIs). However, resistance to quinolones is increasing, so their use should be reserved for infections caused by susceptible bacteria. Adverse effects, including peripheral neuropathy and tendinitis, should be monitored closely.",
                "The studies suggest that cephamycins and cefepime are comparable to carbapenems in terms of clinical cure rates for pyelonephritis caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE). However, higher resistance rates to cephamycins and cefepime may require larger doses or alternative agents.",
                "The RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3rd-generation cephalosporin-resistant (3GCephR) bacteria have shown that:\n\n1. Carbapenems (imipenem, meropenem) are effective in treating 3GCephR-IAI.\n2. Aminoglycosides (gentamicin,",
                "The level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible Carbapenem-resistant Enterobacterales (CRE) is high, based on numerous randomized controlled trials and meta-analyses demonstrating superior clinical response and microbiological eradication rates.",
                "The evidence for the advantage of aminoglycosides over tigecycline for complicated urinary tract infections (cUTI) is inconclusive. Some studies suggest that aminoglycosides may have similar efficacy to tigecycline, while others suggest that tigecycline may have a slightly better safety profile. Ultimately, the choice between these antibiotics depends on individual patient factors and clinician preference.",
                "Plazomicin, a new antibiotic, has shown promise in clinical trials for the treatment of infections caused by Carbapenem-resistant Enterobacterales (CRE), including those that are resistant to colistin. However, more data from larger, randomized controlled trials are needed to definitively establish the superiority of plazomicin over colistin in terms of clinical outcomes, safety, and resistance development. Therefore, the evidence is not yet sufficient",
                "Yes, there are studies suggesting that colistin-carbapenem combination therapy may have a lower 28-day mortality rate compared to colistin monotherapy in patients with Carbapenem-resistant Enterobacteriaceae (CRE) infections. However, the evidence is not definitive, and more research is needed to confirm these findings. It's important to note that individual patient outcomes can vary significantly based on factors such as underlying health conditions and",
                "Cefiderocol is a siderophore cephalosporin antibiotic with activity against Carbapenem-resistant Enterobacterales (CRE). The evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections comes from several clinical studies.\n\nA randomized controlled trial (RCT) by Bekas et al. (2019) showed that monotherapy with cefiderocol led to similar",
                "The retrospective cohort study found that ceftolozane-tazobactam was associated with a higher clinical cure rate (83.3%) compared to polymyxins or aminoglycosides (63.6%) in patients with MDR/XDR P. aeruginosa mixed infections. However, it's important to note that retrospective studies have limitations, and more well-designed studies are needed to confirm these",
                "For severe infections caused by CRPA (Carbapenem-resistant Pseudomonas aeruginosa), the recommended antibiotic regimens include:\n\n1. Polymyxins (e.g., polymyxin B or E) in combination with an aminoglycoside (e.g., gentamicin or tobramycin).\n2. Monotherapy with a newer polymyxin (e.g",
                "For patients with CRAB (Carbapenem-resistant Acinetobacter baumannii) and susceptible to sulbactam but resistant to other antibiotics in the setting of HAP (Healthcare-associated pneumonia) or VAP (Ventilator-associated pneumonia), the suggested treatment options may include:\n\n1. Polymyxins (e.g., colistin or polymyxin",
                "Cefiderocol is an antibiotic with activity against gram-negative bacteria, including those commonly responsible for CRAB (community-acquired or healthcare-associated carbapenem-resistant acinetobacter baumannii) infections. Several studies have shown that cefiderocol is effective in treating CRAB infections, with success rates similar to or superior to other antibiotics such as colistin and tigecycline. However, it",
                "Observational studies suggest that polymyxin-carbapenem combination therapy may be effective in treating CRAB (Carbapenem-resistant Acinetobacter baumannii) infections. However, high-quality randomized controlled trials are needed to provide stronger evidence of its efficacy and safety. The combination therapy may improve outcomes by synergistic effects of both antibiotics against carbapenem-resistant A. baumannii.",
                "CR-GNB (Carbapenem-resistant Gram-negative bacteria) infections require specific antibiotic treatment due to their resistance to commonly used antibiotics. Here are some general principles for antibiotic treatment:\n\n1. Identify the specific CR-GNB causing the infection through laboratory testing.\n2. Choose an antibiotic that is active against the identified CR-GNB.\n3. Consider the site of infection, severity, and patient",
                "For patients undergoing colorectal transplant surgery, preoperative screening typically includes colonoscopy to assess for colon cancer or precancerous lesions. For liver transplant patients, screening may include hepatitis serology, imaging studies like ultrasound or CT scan, and tumor markers like AFP. The specific screening approach may vary depending on individual patient risk factors and transplant type. Always consult with a healthcare professional for personalized medical advice.",
                "The recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with Extended-Spectrum Cephalosporin-Resistant Enterococci (ESCR-E) undergoing colorectal surgery is controversial. Some guidelines suggest considering alternative antibiotics for PAP, while others recommend using a different class of antibiotics altogether, such as aminoglycosides or glycopeptides. Ultimately",
                "The antibiotics that should be reserved for the treatment of extensively resistant bacteria (such as extensively drug-resistant Mycobacterium tuberculosis or carbapenem-resistant Enterobacteriaceae) include:\n\n1. Polymyxins (e.g., colistin)\n2. Aminoglycosides (e.g., amikacin, gentamicin)\n3. Tigecycline",
                "Recommended components for research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates include:\n\n1. Study design: Randomized controlled trials (RCTs) or observational studies.\n2. Study population: ESCR-E colonized SOT candidates.\n3. Intervention: Targeted PAP (pre-transplant antimicrobial prophylaxis)",
                "Yes, a recommendation can be issued for targeted PAP for patients colonized with CRE before surgery to reduce the risk of surgical site infections caused by these bacteria. However, the specific antibiotic choice should be based on local resistance patterns and potential for cross-resistance. Consult local guidelines and infectious disease specialists for the most appropriate antibiotic selection.",
                "A good practice for screening Solid Organ Transplant (SOT) recipients for CRAB (Chronic Renal Allograft Abolition) before surgery is to assess their renal function with regular serum creatinine levels and estimated glomerular filtration rate (eGFR). Additionally, monitoring for proteinuria, hematuria, and signs of allograft dysfunction is essential. If there are concerns, a renal biopsy may be necessary",
                "To investigate CRAB (Clostridioides difficile-related antibiotic-associated bacterial) colonization and targeted PAP (phage-based antibiotic prophylaxis), the panel would suggest designing randomized controlled trials (RCTs) with a placebo or active comparator arm. These trials should include adequate sample size, proper power analysis, and appropriate endpoints to assess the efficacy and safety of targeted PAP in preventing CRAB colon",
                "In transplant surgery other than renal transplant, the suggested duration of post-operative positive airway pressure (PAP) varies depending on the specific type of transplant and individual patient's condition. Generally, it ranges from a few days to several weeks. For example, in liver transplant, PAP may be used for a few days to help prevent respiratory complications. In heart-lung transplant, PAP may be required for several weeks to help the",
                "The risk of Multidrug-resistant Gram-negative bacterial (MDR-GNB) infections in solid organ transplant (SOT) recipients is relatively high due to the use of immunosuppressive medications. These infections can lead to serious complications such as sepsis, organ failure, and increased mortality. Common MDR-GNB pathogens include P. aeruginosa, Acinetobacter baumannii, and Kle",
                "The suggested approach to identify FQR-E carriers before TRUSPB includes:\n\n1. Obtaining a urine culture before the procedure.\n2. Sensitivity testing for fluoroquinolones in the urine culture result.\n3. Considering alternative antibiotics for prophylaxis if FQR-E is identified.\n\nIt's important to note that the decision to test for FQR-E should be based on local",
                "The specific outcome of the trial you're referring to is not readily available in a clear and short answer format, as I would need to access the study's results to provide an accurate response. However, in general, non-blinded trials may be subject to bias, and comparing ciprofloxacin PAP (prostate antimicrobial prostatease) to culture-based PAP (transrectal ultrasound-guided prostate bi",
                "Urinary colonization with MDR-GNB is a significant risk factor for postoperative infections in patients undergoing urologic surgery. These bacteria can cause infections during or after the procedure, leading to increased morbidity and mortality. Preoperative urine screening and appropriate antibiotic prophylaxis can help reduce the risk of these infections.",
                "A comprehensive approach to reducing surgical site infections (SSIs) includes:\n\n1. Preoperative preparation: Optimizing the patient's health, proper wound preparation, and prophylactic antibiotics.\n2. Intraoperative measures: Sterile environment, proper surgical technique, and use of sterile instruments.\n3. Postoperative care: Wound care, early ambulation, and appropriate use of drains and dressings.\n4.",
                "For standard operating procedures (SOPs) related to sampling site technique, it's important to follow these steps:\n\n1. Properly clean and prepare the sampling site.\n2. Use sterile equipment for sampling.\n3. Collect sufficient sample size.\n4. Transport samples to the lab in appropriate containers and at proper temperature.\n\nFor microbiological methods, SOPs should include:\n\n1. Properly handling and transporting samples.",
                "When choosing targeted PAP for CRE infections, consider the following factors:\n\n1. Type and location of the surgery: The risk of surgical site infection (SSI) varies depending on the type and location of the surgery.\n2. Patient risk factors: Factors such as age, comorbidities, and underlying conditions increase the risk of SSIs.\n3. Type and susceptibility of the CRE isolate: The specific type and susceptibility of",
                "Colonization of a patient with bacteria or other pathogens that can cause infections is important to consider before solid organ transplantation (SOT) because these infections can lead to graft failure, increased morbidity, and mortality. Immunosuppressive drugs used after transplantation can weaken the patient's immune system, making them more susceptible to infections. Knowing the colonization status allows healthcare providers to take appropriate measures to prevent or treat"
            ],
            "no additional prompt / context": [
                "Based on the context provided, the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE is a carbapenem (imipenem or meropenem) (strong recommendation for use, moderate certainty of evidence).",
                "The evidence on the treatment of infections caused by 3GCephRE is organized in the context above based on various antibiotics and their recommended use or lack thereof. The context includes recommendations, good practice statements, and a review of the evidence.\n\nThe evidence is primarily derived from observational studies in the hospital setting, including patients with bloodstream infections (BSI) and urinary source of infection. The data are mostly lacking in specific information on the bacterial species and",
                "The large number of observational studies compared carbapenem therapy with quinolones for the treatment of 3GCephRE BSI. However, the studies varied in their design, with some assessing empirical therapy and others targeted therapy, and all reported on mortality as a primary outcome, with some also reporting secondary outcomes. The results of these studies did not show a significant difference in clinical failure between quinolones and carbapenems. Therefore, based on the available",
                "Based on the context provided, there is a conditional recommendation against the use of cephamycins and cefepime for the treatment of 3GCephRE infections, with very low certainty of evidence. No specific studies evaluating cephamycins and cefepime versus carbapenems for the treatment of pyelonephritis caused by 3GCephRE were mentioned in the context.",
                "Based on the context provided, there is a lack of investigator-initiated RCTs specifically evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by third-generation cephalosporin-resistant Enterobacteriaceae (3GCephRE). Therefore, no definitive finding can be made from the RCTs mentioned in the context regarding the efficacy of specific antibiotics for IAI caused",
                "Based on the small study mentioned in the context, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam for susceptible CRE compared with the old antibiotics. However, it is important to note that this evidence is based on one study and more research is needed to confirm these findings. Additionally, the study excluded patients with BSI caused by non-susceptible strains, so the results may not be generalizable to all C",
                "Based on the context provided, there is low-certainty evidence for the inferiority of tigecycline compared with aminoglycosides for cUTI. However, there is no direct evidence on the comparison of aminoglycosides and tigecycline for cUTI specifically. The evidence for aminoglycosides is moderate-certainty for cUTI, but the risk for nephrotoxicity increases after 7",
                "Based on the context provided, there is currently insufficient evidence on the comparative efficacy of plazomicin versus colistin for the treatment of CRE infections. The available data comes from a suspended study that showed no statistically significant differences in all-cause mortality at 28 days between colistin combination therapy and plazomicin combination therapy. However, the study was suspended after two years due to enrolment difficulties, and the results were not sufficient",
                "Based on the information provided in the context, there is low-certainty evidence suggesting that high-dose extended-infusion meropenem-polymyxin combination therapy may offer an advantage over polymyxin monotherapy in the treatment of severe infections caused by CRE, mainly KPC-producing K. pneumoniae. However, there is no clear evidence on the specific comparison between colistin monotherapy and colistin-carbap",
                "Based on the context provided, there is limited evidence directly comparing cefiderocol monotherapy to combination therapy in the treatment of CRE infections. The CREDIBLE RCT mentioned in the context did not present separate results for CRE infections or provide mortality data. Two retrospective studies suggested potential benefits of double carbapenem regimens, but these studies had limitations such as lack of adjustment for confounders and small sample sizes.\n\nOne ret",
                "The retrospective cohort study compared clinical care and nephrotoxicity between 100 patients treated with ceftolozane-tazobactam and 100 patients treated with polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections. The study found that clinical care was higher with ceftolozane-tazobactam (adjusted OR 2",
                "The recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin is to use a combination of two in vitro active drugs (conditional recommendation for use, very low certainty of evidence). No specific combinations can be recommended.",
                "Based on the studies mentioned in the context, there is low-certainty evidence suggesting an advantage of sublactam-based therapy over tigecycline for patients with CRAB susceptible to sulbactam and HAP/VAP. Specifically, several studies have shown that sulbactam-based therapies, such as cefoperazone-sulbactam or ampicillin-sulbactam, are associated with lower mort",
                "Based on the available evidence, we cannot make a definitive recommendation on the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections. The evidence on CRAB infections primarily comes from observational studies with low certainty, and there is a lack of clinical studies directly comparing cefiderocol to other antibiotics for this indication. Therefore, more research is needed to establish the efficacy and safety of cefiderocol for CRAB in",
                "Based on the context provided, there have been observational studies that suggest an association between polymyxin-carbapenem combination therapy and lower 14-day mortality in patients with CRAB infections, particularly when meropenem MICs are <=8 mg/L [164, 180]. However, the evidence for this advantage is considered low-certainty due to the retrospective nature of the studies.\n\nAdditionally",
                "1. Targeted antibiotic treatment: In the absence of pathogen identification, CR-GNB should be targeted among patients considered at high risk for CR-GNB infections. Empiric treatment should balance the need for appropriate therapy and the need to conserve last resort therapies for these bacteria.\n\n2. Antibiotic stewardship considerations: The use of carbapenems for infections caused by 3GcephRE should be considered based on",
                "Based on the context provided, the suggested approach for screening patients undergoing colorectal and liver transplant surgery for Carbapenem-resistant Enterobacteriaceae (CRE) colonization is not clearly defined. The text suggests that the implementation of screening procedures should follow a careful assessment of the local prevalence of CRE colonization and infection, and that a prevalence >=10% may be considered as a cut-off for implementation evaluation. The choice of targeted versus",
                "Based on the available evidence from observational studies, there is an increased association between rectal colonization with ESCR-E and postoperative infections, suggesting that targeted PAP may be effective in reducing SSIs. However, there is a lack of well-designed randomized controlled trials (RCTs) comparing targeted PAP with routine PAP in MDR-GNB carriers. The choice of PAP may also vary according to local protocols and different geographic",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers. The",
                "1. Study Design: Clinical trials with a prospective design are recommended to investigate the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates.\n\n2. Participants: High-risk SOT candidates, specifically those with ESCR-E colonization, should be included in the study.\n\n3. Intervention: The study should investigate the use of targeted PAP regimens tailored to E",
                "Based on the available evidence from the studies mentioned in the context, no definitive recommendation can be issued for targeted PAP for patients colonized with CRE before surgery. The studies do not provide sufficient data on the effects of targeted PAP in CRE carriers undergoing transplant surgery, including information on adverse events and emergence of antibiotic resistance.\n\nHowever, it is important to note that the knowledge of CRE colonization in high-risk patients, such as",
                "It is a good practice to screen all SOT recipients for CRAB before surgery, according to the local epidemiology. The choice of targeted versus universal screening should be based on the local work organization and integrated within antibiotic and diagnostic stewardship guidance. The knowledge of the colonization status of the patient before SOT is essential for early implementation of infection control procedures. Any change in screening procedures should follow a careful assessment of local prevalence of CRAB colonization and infection among patients",
                "The panel suggests designing clinical trials to assess the impact of CRAB (Carbapenem-resistant Acinetobacter baumannii) rectal screening in high-risk surgeries.",
                "Based on the current recommendations by international societies such as the Infectious Diseases Society of America, American Society of Health-System Pharmacists, Surgical Infection Society, and Society for Healthcare Epidemiology of America, the suggested duration of PAP in transplant surgery other than renal transplant is consistent with the standard practice of discontinuing PAP within 24 hours after surgery [3,54,49,50,51,",
                "The risk of MDR-GNB infections in SOT recipients varies depending on the type of transplant and the geographic area. Intra-abdominal infections, especially in the early post-transplant period, pose a significant risk for ESC-ER and CRKP infections, with rates ranging from 6% to 13% and 3% to 10%, respectively [65, 66, 67]. ESC",
                "Based on the context provided, it is recommended to perform rectal screening to identify FQR-E carriers before TRUSPB. This is a conditional recommendation with moderate certainty of evidence. The rationale for this recommendation is that FQR-E colonization is associated with increased rates of post-TRUSPB infectious complications, and targeted PAP (using antibiotics effective against FQR-E) can help reduce the risk of these complications. However",
                "The recently published randomized, non-blinded, multicenter trial compared ciprofloxacin PAP versus culture-based PAP in 1288 patients undergoing TRUSPB, including 15.8% of FQR carriers. The study showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-",
                "The association between urinary colonization with MDR-GNB and postoperative infections in patients undergoing urologic surgery has been well-documented in the literature. Several studies have shown that post-transplant MDR-GNB colonization is a risk factor for infections, suggesting that culture surveillance should be considered after surgery as well, according to local epidemiology and individual risk factors [13, 34, 43, 48,",
                "The reduction of SSIs requires a comprehensive approach that includes both antibiotic-based interventions and best surgical practices. Antibiotic-based interventions should focus not only on targeted PAP but also on heightening stewardship initiatives to monitor and contain the consequences of new prescription patterns, enhance surveillance protocols, improve local adherence to guidelines, and promote a multidisciplinary approach. Best surgical practices include minimization of surgical operative time, regulation of",
                "Based on the context provided, it is recommended to optimize antibiotic-based interventions not only on targeted PAP but also on heightening stewardship initiatives. This includes enhancing surveillance protocols, improving local adherence to guidelines, and promoting a multidisciplinary approach to target SSIs.\n\nRegarding sampling site technique and microbiological methods, the context suggests that improved methods are needed to reduce bias in observational studies and portray the real life,",
                "1. Risk assessment: Identify patients at increased risk for CRE infections, such as those with pretransplant CRE colonization, treatment with broad-spectrum antibiotics in the past 30 days, need for dialysis, or MELD >24.\n        2. Type of transplant: Consider the type of solid organ transplant (SOT) and the associated risk of CRE infections. Intestinal/multivisceral trans",
                "It is essential to know the colonization status of a patient before solid organ transplantation (SOT) for several reasons. First, if a patient is colonized with multidrug-resistant Gram-negative bacteria (MDR-GNB), such as Carbapenem-resistant Acinetobacter baumannii (CRAB), it can increase the risk of postoperative infections. Early identification of colonized patients allows for the implementation of infection control procedures"
            ],
            "additional prompt / context": [
                "The recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE is a carbapenem (imipenem or meropenem) (strong recommendation for use, moderate certainty of evidence).",
                "1. Aminoglycosides: Conditional recommendation for use with moderate certainty of evidence for short durations of therapy.\n2. Intravenous fosfomycin: Strong recommendation for use with high certainty of evidence.\n3. Stepdown targeted therapy for 3GCephRE infections: Good practice statement using old BBLII, quinolones, cotrimoxazole, or other antibiotics based on susceptibility patterns.\n4.",
                "The large number of observational studies comparing carbapenem therapy with quinolones for the treatment of 3GCephRE BSI reported on mortality and secondary outcomes. However, the evidence was insufficient to make a definitive recommendation for or against the use of quinolones for 3GCephRE BSI. Therefore, it is considered good clinical practice to consider quinolones as a stepdown targeted therapy following carbapenems once patients are stabilized,",
                "There is insufficient evidence to recommend the use of cephamycins (e.g. cefoxitin, cefmetazole, flomoxef) and cefepime for the treatment of pyelonephritis caused by 3GCephRE. No recommendation can be issued for ticarcillin-clavulanic acid, temocillin, mecillinam, ampicillin-sulbactam",
                "There is a lack of investigator-initiated RCTs specifically addressing the treatment of IAI caused by 3GCephRE. Existing studies have limitations, such as combined and switched antibiotic treatments, lack of phenotypic and genetic characterization of the isolated bacteria, and insufficient information on infection source. Therefore, it is not possible to provide a definitive finding from RCTs regarding the most effective antibiotics for treating IAI caused by 3GCeph",
                "Based on the small study mentioned in the context, there is moderate-certainty evidence for an advantage of meropenem-vaborbactam for susceptible CRE compared with the old antibiotics.",
                "Based on the context provided, there is low-certainty evidence for the inferiority of tigecycline compared with aminoglycosides for cUTI. However, there is no direct evidence on the comparison of aminoglycosides and tigecycline for cUTI specifically. Therefore, the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI is very low.",
                "No, there is insufficient evidence on the comparative efficacy of plazomicin versus colistin for the treatment of CRE infections. The available data comes from a suspended study that showed no statistically significant differences in all-cause mortality between colistin combination therapy and plazomicin combination therapy. However, more research is needed to make a definitive conclusion.",
                "Based on the available evidence from the AIDA and OVERCOME trials, no statistically significant difference in 28-day mortality was observed between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections (moderate-certainty evidence). However, the use of more than one in vitro active antibiotic might be beneficial.",
                "Based on the available evidence, there is no clear-cut answer on whether cefiderocol monotherapy or combination therapy is superior in the treatment of CRE infections. The CREDIBLE RCT did not show significant differences in clinical and microbiological cure rates between cefiderocol monotherapy and combination therapy, but there are no studies specifically addressing mortality or comparing recently marketed antibiotics with activity against CRE in monotherapy versus combination. Therefore, the decision between",
                "The retrospective cohort study compared clinical care and nephrotoxicity between ceftolozane-tazobactam and polymyxins or aminoglycosides in patients with MDR/XDR P. aeruginosa mixed infections. Ceftolozane-tazobactam was associated with higher clinical care (adjusted OR 2.63, 95% CI 1.31-5",
                "The recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin is to use a combination of two in vitro active drugs (conditional recommendation for use, very low certainty of evidence). No specific combinations can be recommended.",
                "Based on the studies mentioned in the context, sulbactam-based therapy, either as monotherapy or in combination with other antibiotics, is suggested for patients with CRAB susceptible to sulbactam and HAP/VAP. This approach has shown advantages in terms of lower ICU mortality, treatment failure, and microbiological cure in some studies. However, it is important to note that the evidence is of low certainty due to the retrospective nature of",
                "Based on the current evidence, we cannot make a definitive recommendation on the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections due to a lack of sufficient clinical data. The data available are primarily observational studies with low certainty of evidence. Therefore, we conditionally recommend against the use of cefiderocol for the treatment of CRAB infections (low certainty of evidence). For patients with CRAB infections, combination therapy using two",
                "Based on the context provided, there is very-low-certainty evidence for the advantage of double-covering combination therapy, which may include polymyxin and carbapenem, over polymyxin monotherapy in the treatment of CRAB infections. However, most of the data on CRAB rely on low-certainty observational studies, and specific studies on polymyxin-carbapenem combination therapy are limited. Therefore,",
                "1. Target specific pathogens before identification, especially for those at high risk for CR-GNB infections.\n2. Achieve appropriate empirical antibiotic therapy while conserving last resort therapies.\n3. Consider antibiotic stewardship principles, including sparing of new BIBLI and alternatives to carbapenems.\n4. Test against new BIBLI and polymyxins for CR-GNB resistant to all b-l",
                "1. Assess local prevalence of CRE colonization and infection among patients admitted or transferred to the surgical wards. Consider implementing screening procedures if the prevalence is >=10%.\n2. Choose targeted or universal screening based on local work organization and antibiotic and diagnostic stewardship guidance.\n3. Knowledge of colonization status before surgery is essential for infection control procedures.\n4. Consider designing clinical trials to assess the impact of CRE rectal screening in high",
                "Based on the available evidence from observational studies, there is an association between rectal colonization with ESCR-E and postoperative infections. Targeted PAP for MDR-GNB carriers, including ESCR-E, may be effective in reducing SSIs. However, well-designed RCTs are needed to confirm this and improve patient outcomes. One prospective multinational study suggests a potential benefit for etapenem use in ESCR",
                "Based on the context provided, reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules such as ceftazidime-avibactam, ceftolozane-tazbactam, meropenem-vaborbactam, cefiderocol, and imipenem-relebactam, should not be routinely used for targeted PAP in ESCR-E carriers. Car",
                "1. Randomized controlled trial design with sufficient power to detect a significant reduction in post-transplant infections.\n2. Clearly defined inclusion and exclusion criteria, including ESCR-E colonized SOT candidates.\n3. Description of the targeted PAP regimen, including the choice of antibiotics and duration.\n4. Comparison group receiving standard PAP or no PAP.\n5. Outcome measures, including the incidence and severity of post-",
                "Based on the current evidence, a definitive recommendation for targeted PAP for patients colonized with CRE before surgery cannot be issued. However, it is important to consider the potential implications of CRE colonization for infection control and post-surgical treatment. Further research, including clinical trials, is recommended to assess the impact of CRE rectal screening and the optimal approach to targeted PAP for high-risk patients undergoing transplant surgery.",
                "1. Assess local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards.\n2. Consider a prevalence >=10% as a cut-off for implementation evaluation.\n3. Use evidence-based screening protocols, including screening of different body sites.\n4. Choose targeted versus universal screening based on local work organization and integrated within antibiotic and diagnostic stewardship guidance.\n5. Perform MDR-GNB",
                "The panel suggests designing clinical trials to assess the impact of CRAB rectal screening in high-risk surgeries.",
                "The suggested duration of PAP in transplant surgery other than renal transplant is 48-72 hours, according to a good practice statement. However, the evidence supporting this recommendation is of low to very low certainty due to the paucity of data and observational study design. The current recommendation by international societies is to discontinue PAP within 24 hours after surgery.",
                "The risk of MDR-GNB infections in SOT recipients ranges from 3% to 53%, with highest rates observed for intestinal, liver, and pancreas transplantation. Post-SOT infections caused by MDR-GNB are associated with higher mortality compared with their susceptible counterpart. Among nonfermenters, rates of CRAB and MDR PA in bloodstream infections (BSIs) can be up to",
                "Based on the context provided, it is recommended to perform rectal screening to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence).",
                "The trial showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate for ciprofloxacin PAP versus culture-based PAP in all patients. FQR carriers had a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers. However, the study did not",
                "The association between urinary colonization with MDR-GNB and postoperative infections in patients undergoing urologic surgery is well-documented. Culture surveillance should be considered after surgery, according to local epidemiology and individual risk factors. (References: 13, 34, 43, 48, 70, 79)",
                "A comprehensive approach to reducing SSIs involves a combination of antibiotic-based interventions and best surgical practices. This includes minimizing surgical operative time, regulating glucose and temperature, optimizing sterile techniques, managing patient comorbidities, and enhancing surveillance protocols. Additionally, stewardship initiatives should be implemented to monitor and contain the consequences of new prescription patterns, improve local adherence to guidelines, and promote a multidisciplinary approach.",
                "1. Sampling site technique: Proper aseptic technique should be strictly followed during sampling to minimize contamination and ensure accurate results.\n        2. Microbiological methods: Standardized and validated laboratory methods should be used for bacterial identification and antimicrobial susceptibility testing. Continuous quality control and improvement of laboratory methods is essential.\n        3. Timely reporting: Rapid and reliable reporting of microbiological results is crucial for effective infection control and appropriate antib",
                "1. Risk assessment for CRE colonization or infection\n        2. Type of transplant and associated risks\n        3. Available susceptibility profiles for MDR bacteria\n        4. Adverse events and emergence of antibiotic resistance\n        5. Guidelines and recommendations from reputable organizations\n        6. Centers reporting a high incidence of CRE SSIs may consider targeted PAP with specific regimens.\n        7. Limited data comparing PAP regim",
                "1. Knowing the colonization status of a patient before solid organ transplantation (SOT) is essential for early implementation of infection control procedures, reducing the risk of intra-hospital and community spreading of multidrug-resistant bacteria (MDR-GNB), such as CRAB (Carbapenem-resistant Acinetobacter baumannii).\n        2. This information is also relevant for adapting postsurgical empirical treatment in"
            ]
        },
        "metrics": {
            "no additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.10426927455870987,
                    "2_gram": 0.17232945312043874,
                    "3_gram": 0.12203449066382968,
                    "4_gram": 0.08598788681468703
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.23668217296509428,
                        "recall": 0.4109030657231275,
                        "fmeasure": 0.285740394312968
                    },
                    "rouge_L": {
                        "precision": 0.15572278316466392,
                        "recall": 0.2809290035071148,
                        "fmeasure": 0.1908752053324701
                    }
                },
                "METEOR": 0.23717818182947348,
                "BERTScore": {
                    "Precision": -0.003,
                    "Recall": 0.171,
                    "F1_measure": 0.083
                }
            },
            "additional prompt / no context": {
                "BLEU": {
                    "1_gram": 0.11141463788088923,
                    "2_gram": 0.18204904662284616,
                    "3_gram": 0.13031715085607568,
                    "4_gram": 0.09079129596816363
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.24730519574032211,
                        "recall": 0.4196049847717524,
                        "fmeasure": 0.2914223958282858
                    },
                    "rouge_L": {
                        "precision": 0.17372168561673687,
                        "recall": 0.2921140135388925,
                        "fmeasure": 0.2044809352091253
                    }
                },
                "METEOR": 0.2426199338470025,
                "BERTScore": {
                    "Precision": 0.04,
                    "Recall": 0.216,
                    "F1_measure": 0.127
                }
            },
            "no additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.1116387827746325,
                    "2_gram": 0.19336933189889624,
                    "3_gram": 0.163931548964484,
                    "4_gram": 0.1256234803202731
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.31001699337202415,
                        "recall": 0.5580794593246031,
                        "fmeasure": 0.3737613659684049
                    },
                    "rouge_L": {
                        "precision": 0.21925067294698328,
                        "recall": 0.39593237209656973,
                        "fmeasure": 0.26434199635147215
                    }
                },
                "METEOR": 0.3388762426902671,
                "BERTScore": {
                    "Precision": 0.181,
                    "Recall": 0.366,
                    "F1_measure": 0.272
                }
            },
            "additional prompt / context": {
                "BLEU": {
                    "1_gram": 0.12987834851762212,
                    "2_gram": 0.2223006777921877,
                    "3_gram": 0.19539182909036257,
                    "4_gram": 0.1547675704574859
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3626161849895052,
                        "recall": 0.5610202950589221,
                        "fmeasure": 0.4130608756361466
                    },
                    "rouge_L": {
                        "precision": 0.286282730772088,
                        "recall": 0.4293540333026903,
                        "fmeasure": 0.32243401101863295
                    }
                },
                "METEOR": 0.3877577437912271,
                "BERTScore": {
                    "Precision": 0.232,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            }
        }
    }
]